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Summary 
 
There is still an unmet need for the discovery and development of neuroactive 
drugs to treat psychiatric illness. The list of compounds used for treatment today is 
long, yet the often times reported lack of efficacy and the broad spectrum of 
unpleasant side effects are concerning. With my work presented in this thesis I aim to 
explore new routs of drug discovery using the zebrafish model system as valuable tool 
to bridge the gap between bench and bedside. 
 
In the first and second study I exploit the transparency of zebrafish to test the 
utility of synthetic photochemical compounds to modify behavior in a targeted 
fashion. Small molecules that can be activated and inactivated by light are attractive 
targets for drug development since they offer spatiotemporal control and their dose can 
potentially be calibrated instantly and interactively during treatment. I explored remote 
optical control of neuronal activity and behavior and implemented a rapid behavioral 
assay that is designed to provide a readout of neurotropic effects in zebrafish larvae 
(Barber et al., 2016; Trads et al., 2017). 
 
In the third project I studied the grs357 zebrafish mutant as a tool for drug 
discovery. Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis is highly 
correlated with depression and is thought to contribute to the etiology and progression 
of the disease. The grs357zebrafish mutant has a missense mutation that abolishes 
glucocorticoid receptor transcriptional activity and results in a chronically elevated 
stress axis together with behavioral endophenotypes of depression. This mutant 
therefore provides an entry point for research into the pathogenesis of depression and 
for the development of potential drug treatments. To examine how known 
antidepressant compounds affect brain activity of larval zebrafish, I employed brain-
wide, cellular-resolution light-sheet microscopy. With a graph-theoretical approach, I 
extracted network parameters of neuronal activity in both wildtype and grs357 mutant 
fish, following treatment with fluoxetine, ketamine and cycloserine.  
 
Consistent with broad expression of the glucocorticoid receptor throughout the 
brain, I showed that the mutant fish exhibit an altered correlational structure of resting-
state brain activity. Antidepressants differentially affected particular metrics of 
 VII 
functional connectivity. Intriguingly, in grs357 mutant fish, an increased ‘modularity’, 
which represents the degree of segregation of the network into highly clustered 
modules, with fewer functional connections among them, was restored by fluoxetine 
to wildtype levels. With this project I showed that light-sheet imaging of zebrafish 
brain activity combined with graph-theoretical analysis of functional connectivity 
provides a content-rich and scalable approach for studying the neural consequences of 
drug x genotype interactions (Burgstaller et al., 2019).  
 
In summary, the work presented here took advantage of cutting edge methods 
like photopharmacology and cellular-resolution light-sheet microscopy for drug 
discovery in the larval zebrafish. Importantly, apart from the biological findings, these 
methods can be applied to study various compounds and animal models of psychiatric 
disorders. 
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1 Introduction 
 
1.1 Zebrafish as model organism 
The zebrafish (Danio rerio) is an Indian freshwater teleost first introduced to 
laboratory research by Georg Streisinger (Streisinger et al., 1981). Due to the 
development of genetic and molecular techniques, the establishment of genetic mutant 
models of disease and advances in high-resolution functional imaging in vivo and 
pharmacological manipulation of neuronal activity, zebrafish have emerged as a 
promising vertebrate model to study the cellular network architecture in healthy and 
diseased brains. 
Considering zebrafish for neuroscience research in the light of these advances, 
we should take into account the size of the brain and the number of neurons it 
contains. Ideally, the brain of a well-suited model organism should be functionally 
complex and conform to the basic organization of a vertebrate brain, yet it should 
comprise a small number of neurons. The zebrafish brain contains approximately 
100.000 neurons (Naumann et al., 2010) with an average brain size of 300µm x 400µm 
x 800µm. Thus, compared to a human brain with its 1011 neurons, the fish brain offers 
many advantages in order to study the functional connectivity in the whole-brain. 
Sophisticated imaging and light-induced manipulation in an intact, behaving animal is 
possible in larval zebrafish as they are transparent during early development (Ahrens 
et al., 2013; Kubo et al., 2014). Furthermore, with their rich behavioral repertoire 
(Burgess, Schoch, & Granato, 2010; Easter, Jr. & Nicola, 1996; Kubo et al., 2014, 
Orger, Smear, Anstis, & Baier, 2000), it is possible to identify mutant phenotypes and 
to investigate the underlying network properties of functional connectivity in the brain 
with cellular resolution. 
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1.1.1 Stress and depression 
With 350 million people affected worldwide (Marcus et al., 2015), depression 
is listed as fourth leading cause of disease burden by the World Health Organisation 
(Ansorge et al., 2007; Ustun, 2004). It is a debilitating disorder of the central nervous 
system that causes severe social and economic impact to the patient and society 
(Simon, 2003). Affected individuals often experience persistent low mood, sadness, 
guilt, irritability, worthlessness and self-loathing as well as anhedonia, fatigue, weight 
changes, sleep abnormalities, attention deficits, and suicidal thoughts.  
 
The broad spectrum of symptoms and the attempt to elucidate the etiology of 
depression led to a variety of theories concerning the causes of depression. The two 
major neurobiological theories are: a) the monoamine theory and b) the hypothalamus 
– anterior pituitary – adrenal medulla (HPA) axis theory. In the first theory, impaired 
signal transduction is attributed to an imbalance of monoamines (Urani et al., 2005). 
This hypothesis spurred the development of a plethora of antidepressants, like 
selective serotonine reuptake inhibitors (SSRIs), to increase and stabilise 
monoaminergic signalling (Ansorge et al., 2007). These drugs however, are slow in 
onset (several weeks) and often patients do not respond to them at all (Artigas, 2001). 
Because major depression is often associated with a hyperactivated neurobiological 
stress response and corresponding endocrine parameters (Holsboer, 2000; Pariante & 
Lightman, 2008), the second theory focuses on the HPA axis (Fig. 1).  
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Figure 1. HPA-axis. The so-called ‘stress response’ is mediated by the HPA-axis. Increased 
synthesis and release of corticotropin-releasing hormone (CRH) in the hypothalamus promotes the 
release of adrenocorticotropic hormone (encoded by the pomc gene) from the pituitary gland into the 
circulation. Adrenocorticotropic hormone stimulates the production of glucocorticoids in the adrenal 
gland, whose fish homolog is named interrenal organ. In teleost fish and humans, the major 
glucocorticoid hormone is cortisol.  
 
In response to stress, the paraventricular nucleus of the hypothalamus releases 
corticotropin releasing hormone (CRH), which in turn stimulates the anterior pituitary 
gland to secrete adrenocorticotrophic hormone (ACTH). This leads to a release of 
cortisol/corticosterone from the adrenal gland in humans (corresponding to the 
interrenal gland in teleosts). As part of a negative feedback loop, cortisol binds to the 
glucocorticoid receptor (GR) in the hypothalamus and anterior pituitary in order to 
terminate the stress response (Jeanneteau et al., 2012). When individuals are 
chronically exposed to stress, these receptors become desensitised and downregulated, 
which ultimately leads to disrupted negative feedback loops and a disinhibition of the 
HPA axis. As a result, the levels of cortisol, CRH and ACTH are increased together 
with the production of neurotoxic free radicals and a decrease in brain derived 
Source of stress
PVN of hypothalamus
Anterior pituitary gland
Adrenal / interrenal gland
Systemic stress response
CRH
ACTH
cortisol
grs357
mutant
negative 
feedback
no negative 
feedback
wildtype
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neurotrophic factor. Neurobiological consequences may include atrophy of apical 
dendrites, granular cell death in the hippocampus, release of pro-inflammatory 
cytokines from macrophages and microglia, serotonergic dysregulation and an 
increase in monoamine oxidase-A (Meloni et al., 2008; Willner et al., 2013). Together 
with symptoms of memory problems and a disrupted immune system (Belmaker & 
Agam, 2008), depression is considered a heterogeneous disorder and our 
understanding of its etiology and neuropathology remains incomplete (Berton et al., 
2012). There is an unmet need for effective treatment, but the development of 
successful therapeutics is extremely difficult. 
 
1.1.2 Zebrafish and stress-related diseases 
The aim to investigate the link between depression and an elevated HPA axis 
has led to the development of genetic animal models as vital instrument to dissect 
disease etiology and as a platform for therapeutic innovation. However, attempts to 
abolish glucocorticoid activity in mice turned out to be challenging because GR is 
expressed in lungs and disruption is lethal in 90% of new-borns due to respiratory 
failure. Methods like conventional knock-out of one allele, overexpression of antisense 
GR mRNA, central nervous system-specific knockouts, disrupted GR dimerization or 
GR overexpression gave rise to several heterozygous mouse models. Their behavioral 
phenotype however only becomes apparent when mice are exposed to stress, where it 
significantly differs compared to behaviors observed in control animals (Urani et al., 
2005). 
Zebrafish (Danio rerio) are small vertebrate teleosts with a high reproductive 
rate, fast embryonic development as well as a complex set of behaviors (Burgess, 
Schoch, & Granato, 2010; Easter, Jr. & Nicola, 1996; Kubo et al., 2014; Orger, Smear, 
Anstis, & Baier, 2000). Homologies to higher vertebrates, such as humans, in key 
genetic, physiological, and behavioral features (Griffiths et al., 2012; Randlett et al., 
2015) have rendered them extremely useful as a model organism in neurobiology. Our 
lab identified an adult viable homozygous GR mutant grs357 in a genetic screen (Muto 
et al., 2005) with a single basepair change that disrupts transcriptional activity of the 
receptor. In these mutants, the HPA axis is chronically elevated due to a disrupted 
INTRODUCTION 
 
 
6 
negative feedback loop (Fig. 2). The receptor can still bind cortisol and translocate to 
the nucleus, but downstream regulation of target genes is impeded (Ziv et al., 2013).  
 
Figure 2. Hyperactivated HPA-axis in grs357 zebrafish mutants. The grs357 zebrafish mutant 
harbors a missense mutation that abolishes glucocorticoid receptor transcriptional activity and negative 
feedback on the stress response, which results in a chronically elevated stress axis together with 
endophenotypes of depression. 
 
Morphologically the larval mutants cannot be distinguished from their 
heterozygous siblings, except for their inability to perform visual background 
adaptation (VBA) (Muto et al., 2005). This means that in response to a bright 
background the mutants are not able to contract their melanophores to hide from 
potential predators (Neuhauss et al., 1999). For experimental procedures, this is useful 
in the sense that mutants can be identified by color at the larval stage and no genetic 
sequence analysis needs to be performed. Homozygous GR mutation becomes 
apparent in the adult by elevated levels of CRH, ACTH and cortisol. Additionally, a 
blunted suppression of cortisol after application of the synthetic GR agonist 
dexamethasone has been described as well as less exploratory behavior, increased 
Source of stress
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periods of immobility, reduced tank wall preference (thigmotaxis) and lack of 
habituation when placed in an unfamiliar environment, like a novel tank (Ziv et al., 
2013). In larval grs357 mutants, spontaneous locomotion over a period of 24 hours is 
reduced, but the startle response to unknown auditory stimuli is increased (Griffiths et 
al., 2012).  
Heterozygous larvae display an intact VBA (Griffiths et al., 2012) and their 
cortisol level as adults is only marginally higher compared to wildtype fish (Ziv et al., 
2013). The endocrine stress level in both, larval and adult fish could be normalized 
after treatment with the antidepressant SSRI fluoxetine. Cause and effect in the 
association of antidepressants and the HPA axis have not been fully disentangled. 
Changes in behavior of treated fish were evident almost immediately. But CRH, 
ACTH and cortisol levels were only reduced after continuous treatment for 2 weeks 
(Griffiths et al., 2012). A slow time course of drug action can also be observed in 
human patients, but the fast effect on fish behavior may be due to some other, yet 
unknown mechanism. Griffiths et al. (2012) suggest other targets of the SSRIs, for 
instance the serotonergic population of neurons in the raphe nucleus. With functional 
whole-brain imaging, I hope to gain further insight into the mechanism of 
antidepressant drug action.   
 
1.1.3 GIRK channels and their role in depression research 
  For neurons to function normally, a well-balanced interplay between excitatory 
and inhibitory signals is necessary (Trevelyan & Watkinson, 2005). Ionotropic 
glutamate receptors like NMDARs (N-methyl-d-aspartate receptors) and AMPARs (α-
amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors) are typically located 
in the postsynaptic density of dendritic spines and play a role in excitatory signal 
transmission. Ionotropic GABA (γ-aminobutyric acid type A) and glycine receptors 
that are located on the soma and dendritic shafts mediate fast inhibitory signals 
(Trevelyan & Watkinson, 2005). G protein-coupled inwardly rectifying potassium 
(K+) channels (GIRK) are expressed perisynaptically outside the postsynaptic density 
in the spine and on the shaft (Lujan at al., 2009), where they balance excitatory and 
inhibitory signals by mediating slow inhibitory postsynaptic currents (sIPSC). 
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GIRK channels are members of a large family of inwardly rectifying K+ 
channels. But what does inward rectification mean? At the channel’s reversal 
potential, the equilibrium potential for K+ at which no current flows (EK), the slope of 
the current-voltage relationship changes. Rectification refers to the fact that the 
outward current is considerably smaller when the membrane potential of the cell is 
above EK compared to the inward current when the membrane potential is below the 
channel’s reversal potential. Intracellular Mg2+ and polyamines that occlude the central 
pore at potentials above EK are responsible for this effect (Yamada et al., 1998). With 
the small outward K+ current, GIRK channels decrease excitability of neurons at 
physiological conditions because the resting membrane potential is typically positive 
to EK. The channels are activated by stimulating their G protein-coupled receptors 
(GPCRs). This happens upon release of several neurotransmitters like acetylcholine, 
dopamine, opioids, serotonin, somatostatin, adenosine and GABA. The GPCRs are 
specifically coupled to pertussis toxin (PTX)-sensitive heterotrimeric G proteins. 
These proteins release Gβγ dimers that bind to and thereby open GIRK channels 
(Huang et al., 1995; Inanobe et al., 1995; Logothetis et al., 1987; Pfaffinger et al., 
1985; Reuveny et al., 1994; Wickman et al., 1994). There are four subunits, GIRK1-4 
expressed throughout the body, that form homo- or heterotetramers. In the central 
nervous system (CNS), GIRK channels are comprised of GIRK1/2 heteromers (Lesage 
et al., 1994; Krapivinsky et al., 1996), whereby GIRK2 has been shown to play the 
primary role in generating GIRK currents in the hippocampus, cerebellum, substantia 
nigra, locus coeruleus and ventral tegmental area (Cruz et al., 2008; Koyrakh et al., 
2005; Labouèbe et al., 2007; Lüscher et al., 1997; Marker et al., 2006; Slesinger et al., 
1997; Torrecilla et al., 2002).  
In order to understand the role of GIRK channels in disease, emphasizing their 
physiological role is indispensable. When GIRK channels function at basal activity, 
they shift the membrane voltage by -8mV and thereby hyperpolarize the resting 
membrane potential. This decrease in electrical excitability shapes the functionality of 
neuronal networks in several brain regions. Physiological activation of the channel 
leads to another level of inhibition in signal processing (Lüscher et al., 1997). The 
well-orchestrated interplay of membrane excitation and inhibition is disrupted when 
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GIRK channel function is altered. Without GIRK functioning, neurons show excessive 
excitability and produce symptoms of epilepsy (i.e. seizures). When selectivity of 
GIRK channels is lost, irregular ion fluxes, such as Na+ influx, trigger cell death as it 
is observed in Parkinson’s disease (Harkins et al., 2002; Mazarati et al., 2006; Siarey 
et al., 1999; Signorini et a., 1997).  
The antidepressant SSRI fluoxetine causes inhibition of GIRK channels. 
Therefore, there might be a link to episodes of major depressive disorder (Hibino et 
al., 2009). SSRIs have a rapid effect on extracellular serotonin (5-HT) levels but why 
therapeutic drug action in patients is slow remains to be investigated. Some attempts 
have been made using cellular assays of 5-HT1A receptor responses in serotonergic 
neurons of the dorsal raphe nucleus (DRN). Using electrophysiological recordings, 
Cornelisse et al. (2007) could show that the 5-HT1A response is decreased in mice 
chronically treated with fluoxetine, but receptors were not downregulated. This class 
of receptors acts on G proteins that target GIRK channels and cause them to 
hyperpolarize the membrane potential and thereby decrease excitability. This effect 
seems to be independent of the animals’ level of stress it is exposed to. 
Pharmacological treatment and the etiology of depression seem to diverge but because 
there is no evidence for changes in 5-HT1A expression in anhedonic mice the receptor 
might not directly affect the depressive phenotype. However, SSRIs seem to be 
involved in decreasing excitability by affecting GIRK channel expression in 
serotonergic neurons activated together with 5-HT1A. Excitability of dorsal raphe 
neurons and release of serotonin is then increased after treatment with fluoxetine, 
because inhibitory inputs from numerous metabotropic receptors are reduced due to a 
downregulation of GIRK (Cornelisse et al., 2007). The therapeutic effect of 
antidepressants as reuptake inhibitors of norepinephrine and/or serotonin in the brain 
may be complemented by inhibition of GIRK channels. This makes them an intriguing 
new therapeutic target and opens up the possibility to develop effective new drugs to 
treat depression and other psychiatric disorders (Kobayashi et al., 2004). Novel tools, 
such as photoswitchable compounds that selectively open or close GIRK channels 
may further increase our understanding of GRIK channel function in disease and help 
to establish the link between these cellular observations and brain function underlying 
behavior.  
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1.2 Methods for drug research in the zebrafish 
In the present work, I introduce methods to advance the zebrafish system as a 
powerful model organism for innovative therapies to treat major depression and 
anxiety disorders. In my research, I exploit the transparency of zebrafish larvae’s body 
to test the utility of synthetic photochemical compounds to modify behavior in a 
targeted fashion. Using a photoswitchable GIRK channel agonist, I aim to explore 
remote optical control of neuronal activity and behavior and implement a rapid 
behavioral assay that is designed to provide a readout of neurotropic effects in 
zebrafish larvae. Small molecules that can be activated and inactivated by light are 
attractive targets for drug development (Luján et al., 2014; Velema et al., 2014) since 
they offer spatiotemporal control and their dose can potentially be calibrated instantly 
and interactively during treatment.  
Whole-brain light-sheet imaging is another powerful tool to study different 
genotypes and drugs in the larval zebrafish. Screening of drug x genotype interactions 
using grs357 mutants is opening up the possibility of identifying novel therapeutic 
avenues for the treatment of stress-related disorders. Together with a sophisticated 
analysis of brain network structure using a graph-theoretical approach, I hope to 
accelerate our understanding about the effects of neuroactive compounds on the 
nervous system and implement a methodological pipeline to use the zebrafish as 
model organism for drug discovery. Together, these fundamental studies are designed 
to fulfil the criteria to establish the zebrafish as a powerful neuropsychiatric model 
system.  
 
1.2.1 Remote optical control of behavior with a photoswitchable 
neuroactive compound 
Light is impressive in its temporal and spatial precision when transferring 
information and ties together chemistry, physics and biology as one of the most 
fascinating phenomena. Nature and its ancient biochemical pathways gave rise to 
numerous photoreceptive systems, e.g. human vision which use molecular 
photoswitches, like retinal, that exist in different states of isomerization depending on 
irradiation. In evolution, these so called chromophores proved to be useful tools in 
INTRODUCTION 
 
 
11 
biological systems and thus remained unaltered. They absorb wavelengths from UV to 
near-infrared, are involved in building up ionic gradients and act on enzymes, ion 
channels or proteins. They control many biological functions, yet only a few natural 
chromophores exist. A new branch of chemistry, photopharmacology, gave rise to a 
variety of highly tunable synthetic photoswitches that are either covalently attached to 
or noncovalently interactive with a target structures. Thereby, they put proteins, G 
protein coupled receptors (GPCRs), ion channels, membranes, transporters, enzymes, 
parts of the cytoskeleton, lipids, and other native biopolymers under optical control 
(Broichhagen et al., 2015; Fehrentz et al., 2011; Kramer et al., 2013; Velema et al., 
2014).  
Designing such photoswitches is quite complex since switching needs to be 
reliable over many cycles without being associated with phototoxicity. Initial 
isomerization of a bistable switch by irradiation at a certain wavelength needs to be 
reversible at another wavelength to turn it on and off, unless a thermally unstable 
photoswitch is designed that spontaneously turns itself off when irradiation stops. The 
most suitable technique can be determined by the biological question to be tackled. 
The photoswitch then needs to be incorporated into the biological structure of interest 
to act as agonist, antagonist or blocker in one state and be inactive in the other 
configuration. Development of these tools requires skills in protein engineering and 
know-how about solubility and stability of these molecules. When targeting 
intracellular structures one has to ensure permeability of the molecule or design it in a 
way so it can actively be transported across the membrane or be microinjected. 
Additionally, synthesizing these photopharmaceuticals should be low in cost and time 
consumption. The wavelength of a photoswitch has to be compatible with the 
biological sample and the methods used in research, e.g. when performing 
fluorescence imaging experiments in neurobiology the switching wavelengths and 
fluorophore excitation/emission wavelengths should be orthogonal (Broichhagen et al., 
2015; Fehrentz et al., 2011; Velema et al., 2014).  
Taking all these criteria into account, synthetic photoswitches that are properly 
designed and made available through well-planned and efficient syntheses, provide a 
powerful tool to study drugs or drug targets and to infer causality when switching the 
compounds on and off.   
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1.2.2 Light-sheet microscopy 
While a myriad of techniques allow the recording of single neurons or 
proximal populations of neurons, distal connections can be easily missed (Ahrens et 
al., 2013).  To grasp the whole complexity of neuronal interaction that drives behavior 
it is key to record as many single units as possible, irrespective of their location in the 
brain (Ahrens & Engert, 2015). Combined with genetically encoded calcium sensors, 
the transparent and small-sized brains of larval zebrafish (800 x 500 x 300 µm, 
approximately 100 000 neurons) enable whole-brain, functional, non-invasive in vivo 
imaging at cellular and millisecond resolution (Orger & Portugues, 2016). In general, 
2-photon microscopy is the gold-standard however, its single point scanning 
mechanism is a double-edged sword. On the one hand, it only excites one point in 
space, thereby reducing photobleaching and increasing depth penetration. On the other 
hand, it becomes increasingly slow in larger volumes, where an increase in speed 
would result in fewer collected photons and thus a higher signal-to-noise ratio 
(Bennett & Ahrens, 2016). Light-sheet microscopy overcomes this issue by 
illuminating an entire plane by means of a sheet of light, generated for instance by a 
galvanometer scanning system. For good coverage of the brain and avoidance of the 
eyes, 1-2 excitation objectives are placed orthogonally to the detection objective. This 
allows vertical scanning of the sample (again via a galvanometer system) at a speed of 
1-2 orders of magnitude faster than conventional 2-photon microscopy (Ahrens et al., 
2013).  
The microscope was custom-built (Fig. 3) by several laboratory members and 
had not yet reached completion at the start of this project. One major task was thus to 
optimise acquisition and develop a user protocol. The light-sheet microscope consists 
of two orthogonal excitation arms for frontal and lateral scanning, and a detection arm 
imaging from above. A laser beam (473nm wavelength, 3-5mW power) is split by a 
dichroic mirror and guided to the excitation arms by six di-electric mirrors. There, two 
pairs of mirror galvanometers oscillate horizontally and vertically, to create a sheet of 
light and scan the sample in the z plane, respectively. Two serial lenses act as a 
pinhole and focus the sheet into the back aperture of a 4x objective. The detection arm 
consists of a 20x detection objective, a piezoelectric component to adjust the focus 
(10V displacement, corresponds to a 400µm range in z), a tube lens, fluorescence 
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filter, and an Orcaflash 4.0 sCMOS camera. The chamber containing the sample sits 
on a lab jack stage, which is brought into the field of view of the camera by x, y, and z 
actuators (Fig. 4).  
 
 
Figure 3. Schematic of the custom-built light-sheet microscope. 
 
 
camera Orcaflash
4.0 sCMOS
fluorescence filter
525 / 50
tube lens
180mm focal length
piezo
400µm range
20x Olympus
detection objective
sample in minimum
beam waist cross
Z-axis actuator
Lenses focal length
15mm (L) 75mm (R)
4x Olympus
excitation objectives
Cobolt laser 473nm λ
3-5mW power
Galvo V pair
beam pathway
beam splitter
dielectric mirror
(1 of 6)
filter wheel
Galvo N pair
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Figure 4. Light-sheet microscope and sample preparation. (a) Close-up view of stage, sample, 
excitation and detection objectives. (b) beam cross on head of larva (c) dorsal view of embedded larva 
in a custom chamber (d) side view of location in z of larva in chamber. For a and b, blue indicates laser 
beams. For c and d, yellow indicates a block of agarose cut along dashed lines, immersed in Danieau’s 
solution (blue).  
The experimental approach in my studies consisted of 5 min recordings of 
spontaneous whole-brain activity in grs357 mutants and wildtype fish at baseline and 
after 1.5h and 3h incubation with drugs (i.e. fluoxetine, ketamine, cycloserine) to 
evaluate their effect on functional connectivity in the neuronal network. When not 
locked to the temporal sequence of a stimulus or behavior, analysis of functional 
whole-brain imaging data is still constrained. Firstly, collected data files are of a vast 
size, requiring highly efficient data storage and processing facilities. Secondly, an 
issue in neural network research using brain-wide single-cell-resolution functional 
imaging is its complex representation in high-dimensional space. In order to extract 
functionally relevant features comprehensively and uncover major patterns in the data, 
I applied the graph theory, which I will explain in further detail in the next chapter of 
this thesis.  
To examine functional connectivity, four-dimensional imaging stacks 
(dimensions being: time, z- , y- and x- plane) were split into time series of single 
planes and corrected for motion artefacts using an adapted version of the CaImAn 
package (Pnevmatikakis et al., 2017; Giovannucci et al., 2019). In brief, this consists 
of a rigid transformation, which grossly rotates the images in the x- and y- plane, 
followed by an optic flow transformation for finer features. This was followed by the 
first steps of data analysis, which include segmentation of the brain and extraction of 
regions of interest (ROIs). Voxelization is one method that is simple to implement, 
and reduces the number of features significantly, however, it may not separate 
neighbouring cells perfectly and thus create a bias in the temporal activity of that 
voxel. Manual neuron segmentation is usually region-of-interest selection based and 
outdated due to its time-consuming and heuristic nature (Mukamel et al., 2009). 
Therefore, the method used in this project was automated neuron segmentation that is 
more computationally demanding, but can be achieved for instance based on local time 
series correlations of pixels (Portugues et al., 2014). Extracting the activity traces of 
selected neurons is the first step to explore changes taking place within the neuronal 
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network in response to drug treatment and leads the way to using zebrafish as a 
valuable tool for drug discovery. 
 
1.2.3 Graph-theoretical analysis of whole-brain functional connectivity 
Exploring the activity of single cells over time by looking at their activity 
traces is crucial, yet not sufficient when facing the challenge of actually quantifying 
changes happening on a whole-brain level. To use the zebrafish as a tool to study drug 
effects on the neuronal network, I chose graph theory as a method to describe and 
explore the topological organization of functional connectivity. It was further applied 
to extract and quantify differences between zebrafish genotypes and changes taking 
place in response to treatment with neuroactive compounds.   
 
Graph theory first appeared in the literature in 1736, when Leonhard Euler 
used this theoretical concept, which describes the pairwise relationship between 
objects to solve the “Königsberg Bridge Problem” (Euler, 1736).  By representing the 
map of the city of Königsberg and its topographic structure as a topological graph with 
four nodes and seven edges (the bridges), Euler (1736) could conclude that it is not 
possible to traverse the seven bridges over the river Preger in a single trip without 
doubling back, starting the trip in the same place where it should end.  
 
Several fields still use these concepts today to quantify complex relations, 
ranging from social sciences to biology and especially neurosciences (Boccaletti et al., 
2006, Schweitzer et al., 2009, Watts & Strogatz, 1998). Graph theory is a powerful 
way to describe the functional organization of the brain by treating the brain as a 
graph, a mathematical structure composed of a set of nodes (brain regions or cells) 
joined together in pairs by edges, (functional connectivity between the brain regions or 
cells) (Watts & Strogatz, 1998). To obtain information about functional associations 
between single cells or brain regions, measurements of the temporal correlation 
between activity traces of cells can be extracted from light-sheet neuroimaging data. 
With this information, graph-theoretic techniques can be applied to model brain 
networks and study their underlying topological properties. Graphs and their edges can 
be undirected or directed, depending on the flow of information, and weighted or 
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unweighted. The Information content of brain images acquired with light-sheet 
microscopy allows the construction of a weighted but undirected network, because 
directionality cannot be inferred from the data. Here, the weight of this network is 
dependent on the strength of correlation between activity traces. The brain is 
functionally organized as a highly complex network and its segregation and 
integration of information processing can be described by a variety of standard 
metrics, whose differences between genotypes and changes over drug treatment give 
insight into the topological network structure of the brain (He & Evans, 2010). 
 
The study of network systems has recently gained attention due to many 
studies focusing on local properties of networks, such as clustering (Watts & Strogatz, 
1998), degree distributions (Barabasi & Albert, 1999; Amaral et al., 2000) and 
correlations (Pastor-Satorras et al., 2001; Newman, 2002). There have also been 
studies that examine large-scale properties such as path lengths (Watts & Strogatz, 
1998), percolation (Cohen et al., 2000; Callaway et al., 2000) or hierarchy (Ravasz & 
Barabasi, 2003; Clauset et al., 2008). Among these metrics, however, the ones 
attracting by far the most attention are the clustering coefficient, characteristic path 
length, modularity or community structure and small-worldness (Fig. 5) (Liao, 
Vasilakos & He, 2017). The clustering coefficient quantifies the extent of local 
cliquishness or local efficiency of information transfer in a network, the capability for 
parallel information propagation in terms of global efficiency can be described by the 
characteristic path length. There are different classes of networks, such as regular, 
small-world, and random networks, that can be distinguished based on clustering and 
characteristic path length (Liao, Vasilakos & He, 2017). 
 
A small-world network (Fig. 5b) has a shorter characteristic path length than a 
regular network (high clustering and long path lengths) but a greater local 
interconnectivity than a random network (low clustering coefficient and short path 
lengths). Nature appears to have designed the functional organization of the brain with 
such small-world network characteristics because it allows highly efficient local 
information processing in specialized modules and global integration at the same time 
and at a relatively low wiring cost (Liao, Vasilakos & He, 2017; Watts & Strogatz, 
1998). Many networks are found to possess communities or modules, groups of nodes, 
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which have relatively dense inter-connections but connections between the modules 
are sparser (Boccaletti, Latora & Moreno, 2006). Community structure together with 
the characteristic path length and overall clustering shape the small-world properties of 
a network and are of fundamental interest in these systems because of their functional 
implications. Modules in a neuronal network, for instance, might correspond to 
circuits that perform certain tasks. Small-worldness, which is shaped by the underlying 
clustering and characteristic path length, may indicate the balance and efficiency 
between local information processing and global integration (Newman, 2013; He & 
Evans, 2010).  
 
         
Figure 5. Network properties. (a) Modules in a network refer to a group of nodes with dense intra-
group connections and sparse between-group connections. The optimal community structure is a 
subdivision of the network into non- overlapping groups of nodes in a way that maximizes the number 
of within-group edges and minimizes the number of between-group edges. The modularity is a measure 
that quantifies the degree to which the network may be subdivided into such groups. The clustering 
coefficient is equivalent to the fraction of node’s neighbors that are neighbors of each other. It is a 
measure of segregation that describes clustered connectivity around individual nodes. The overall level 
of clustering in a network is the average of the local clustering coefficients of all the vertices. The 
characteristic path length is the minimum number of edges between two nodes in the network. The 
lengths of the paths indicate the potential for functional integration between nodes, with shorter paths 
implying stronger potential for integration. (b) A regular network (left) with regular connections has a 
Regular Small-world Random
a
b
Clustering Path lengthModularity
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high clustering coefficient and a long characteristic path length. The random network (right) with 
random connections has a low clustering coefficient and a short characteristic path length. A small-
world network (middle) lies between those two. It contains a large number of short connections with a 
few long connections and thus exhibits a high clustering coefficient with short characteristic path 
lengths. Figure adapted from Liao, Vasilakos, & He (2017). 
By quantifying these network parameters using the graph-theoretical approach, 
we gain insight into genotype differences and drug effects, as well as drug x genotype 
interaction effects in the correlational structure of brain-wide imaging data. For this 
purpose, functional connectivity graphs were constructed for each recorded brain in 
which each node represents a cell (ROI) and each edge between two cells represents 
the correlation of their activity traces. By combining the graph-theoretical method with 
light-sheet imaging data as a scalable approach to explore various genotypes and 
compounds, I hope to introduce the zebrafish model system as a powerful tool to 
discover novel therapeutic procedures. 
 
1.3 Aims of the thesis 
  The identification of a zebrafish experimental model with a mutation in the 
glucocorticoid receptor allows researchers to investigate the pathogenesis of 
depression. Novel tools, like photoswitchable compounds enable us to induce changes 
in neuronal activity remotely and with spatial and temporal precision. Light-sheet 
microscopy combined with a graph-theoretical analysis approach opens up the 
possibility to study brain-wide functional connectivity. Increased computational power 
allows us to handle huge datasets like whole-brain recordings with cellular resolution, 
and promotes the study of various disease genotypes and neuroactive compounds with 
the aim to implement the zebrafish model system as a vehicle for drug discovery. In 
the framework of this dissertation, I contributed to three publications:  
 
  In the first study, I contributed to the development of a photoswitchable 
agonist (LOGO) that enables the optical control of GIRK channels with temporal and 
spatial precision. Inhibition of GIRK channels effectively increases neuronal 
excitability. Thus, the channel might be an interesting new target for drug 
development and further increase our understanding of depression and new treatment 
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options. I tested the photochemical in vivo and designed a behavioral protocol to 
evaluate the compound’s potential to remotely and non-invasively modify locomotor 
behavior in the zebrafish. This behavioral assay is designed to provide a standardized 
readout of neurotropic effects in zebrafish larvae. With this assay, drug treatments or 
genetic modifications can immediately be classified by phenotype and mechanism of 
action can further be investigated. 
 
 In the second study of this dissertation, I was involved in a follow up project to 
develop a GIRK channel photoswitch that can be controlled with visible light. For 
optical control of the fist LOGO, potentially harmful UV irradiation was applied to 
inactivate the photoswitchable agonist. I contributed to discussions with valuable input 
about in vivo studies to further improve the design and application of the 
photoswitches. I also developed a new experimental protocol for the standardized 
assay to test the second version of LOGO, VLOGO (Visible Light Operated GIRK 
channel Opener) in our behavioral setup. VLOGO can be operated with visible light 
and therefore it is a valuable addition to implement these compounds for research in 
biological systems, e.g. drug discovery in the larval zebrafish. 
In the main study of my thesis, I exploit the transparency of the body of 
zebrafish larvae to explore functional whole-brain connectivity with light-sheet 
microscopy. I combined this with a graph-theoretical analysis approach to quantify 
changes in brain network structure. Initially, I studied behavioural differences between 
wildtype fish and the grs357 zebrafish mutant. This mutant harbors a missense mutation 
that abolishes glucocorticoid receptor transcriptional activity and results in a 
chronically elevated stress axis. Dysregulation of the stress axis is highly correlated 
with depression and behaviorally implements in the fish as increased immobility in the 
novel tank test as well as reduced exploration. I recorded brain activity of these fish 
with cellular resolution light-sheet microscopy and applied graph theory to reveal 
differences between genotypes. This allowed me to quantify whole-brain network 
parameters of functional connectivity and revealed that grs357 mutant brains are 
organized in a greater number of functional modules with dense connections within 
these modules and sparse connections between the modules compared to wildtype fish. 
Moreover, I found that with the time spent in the experimental setup, fish might 
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experience stress, which I could extract and quantify as reduced clustering and small-
worldness of the functional connectivity network with longer path lengths in the grs357 
mutant compared to wildtype fish. As a next step, I examined how known 
antidepressant compounds affect brain activity of larval zebrafish. For this purpose, I 
extracted network parameters of neuronal activity in both wildtype and grs357 mutant 
fish, following treatment with fluoxetine, ketamine and cycloserine. Consistent with 
the broad expression of the glucocorticoid receptor throughout the brain, I show that 
antidepressants differentially affected particular metrics of the activity graphs, with 
some treatments restoring mutant brain activity to wildtype levels. From this, I 
conclude that light-sheet imaging of zebrafish brain activity is a content rich and 
scalable approach for studying the neural consequences of drug x genotype 
interactions in psychiatric disorders. Together, the results of my thesis suggest that the 
zebrafish model system can be advanced as a powerful discovery vehicle for drugs and 
innovative therapies.  
The following chapter of my dissertation contains the manuscripts for these 
three studies. The first study, Barber et al., 2016 has been published in the peer-
reviewed journal Chemical Science (Optical control of neuronal activity using a light-
operated GIRK channel opener (LOGO)). The second study, Trads et al., 2017 was 
published in the peer-reviewed journal Organic & Biomolecular Chemistry (Optical 
control of GIRK channels using visible light). My main research project has recently 
been published in BioRxiv (Light-sheet imaging and graph analysis of antidepressant 
action in the larval zebrafish brain network, Burgstaller et al., 2019). 
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2 Publications 
2.1 Optical control of neuronal activity using a light-operated GIRK 
channel opener (LOGO) 
 
Barber, D. M., Schönberger, M., Burgstaller, J., Levitz, J., Weaver, C. D., Isacoff, E. 
Y., Baier, H. & Trauner, D. (2016). Optical control of neuronal activity using a light-
operated GIRK channel opener (LOGO). Chemical Science, 7(3), 2347-2352. 
 
 
Reproduced by permission of The Royal Society of Chemistry 
 
 
My involvement in this field started with the generation and in vivo testing of 
the photoswitchable GIRK channel agonist LOGO (the Light Operated GIRK- 
channel Opener) that allows remote optical control of the channel with UV and blue 
light. In collaboration with the synthetic chemistry laboratory of Dirk Trauner (LMU 
Munich), I developed a behavioral assay (Fig. 6) to implement the zebrafish nervous 
system as a tool to study photoswitchable drugs and learn about GIRK channel 
function in vivo. Behavioral experiments were carried out in the DanioVision system 
purchased from Noldus, using the EthoVision XT Version 10.1 software. Larvae were 
sorted into 96-well plates using disposable pipettes, and allocated according to a 
randomized plate position paradigm to reduce spatial bias. To prevent the system from 
overheating, the chamber that comprised the plate was connected to a home-made 
cooling system which set the temperature constantly to 25ºC. Acquisition was 
controlled via the EthoVision XT software with a sampling rate of 30 frames per 
second using an infrared-sensitive digital FireWire camera. 
With these experiments, we show that this photochemical affects locomotor 
behavior dependent on the wavelength of the illumination. Switching the wavelength 
of the light from blue to UV turns the compound from an active to an inactive state 
and thus leads to a reversible change in locomotor behavior.  
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Figure 6. Behavioral assay to test photoswitchable properties of the GIRK channel agonist 
LOGO. Animals were let 2 minutes to adjust to the 96-well plate before the recoding started for 8 
minutes. The first 10 seconds after blue or UV light pulses of the last 3 cycles were analyzed to quantify 
locomotor activity of the fish.  
We hope this methodological approach of testing photoswitchable compounds 
in a behavioral assay will chart a new route for the discovery of neuroactive 
pharmaceuticals. Including different disease genotypes into the assay may also support 
the development of therapeutic approaches to psychiatric illness in the future.  
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Optical control of neuronal activity using a light-operated GIRK 
channel opener (LOGO)†
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Weaverd, Ehud Y. Isacoffc,e, Herwig Baierb, and Dirk Traunera
Dirk Trauner: dirk.trauner@lmu.de
aDepartment of Chemistry and Center for Integrated Protein Science, Ludwig Maximilians 
University Munich, Butenandtstraße 5-13, 81377 Munich, Germany
bMax Planck Institute of Neurobiology, Am Klopferspitz 18, 82152 Martinsried, Germany
cDepartment of Molecular and Cell Biology and Helen Wills Neuroscience Institute, University of 
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Abstract
G-protein coupled inwardly rectifying potassium channels (GIRKs) are ubiquitously expressed 
throughout the human body and are an integral part of inhibitory signal transduction pathways. 
Upon binding of Gβγ subunits released from G-protein coupled receptors (GPCRs), GIRK 
channels open and reduce the activity of excitable cells via hyperpolarization. As such, they play a 
role in cardiac output, the coordination of movement and cognition. Due to their involvement in a 
multitude of pathways, the precision control of GIRK channels is an important endeavour. Here, 
we describe the development of the photoswitchable agonist LOGO (the Light Operated GIRK-
channel Opener), which activates GIRK channels in the dark and is rapidly deactivated upon 
exposure to long wavelength UV irradiation. LOGO is the first K+ channel opener and selectively 
targets channels that contain the GIRK1 subunit. It can be used to optically silence action potential 
firing in dissociated hippocampal neurons and LOGO exhibits activity in vivo, controlling the 
motility of zebrafish larvae in a light dependent fashion. We envisage that LOGO will be a 
valuable research tool to dissect the function of GIRK channels from other GPCR dependent 
signalling pathways.
Graphical Abstract
†Electronic Supplementary Information (ESI) available: Experimental procedures and characterisation data. See DOI: 10.1039/
x0xx00000x
Correspondence to: Dirk Trauner, dirk.trauner@lmu.de.
HHS Public Access
Author manuscript
Chem Sci. Author manuscript; available in PMC 2017 January 13.
Published in final edited form as:
Chem Sci. 2016 ; 7(3): 2347–2352. doi:10.1039/C5SC04084A.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Introduction
G-protein coupled inwardly rectifying potassium (GIRK) channels are an integral link 
between metabotropic and ionotropic pathways in neurons. They constitute a subclass of 
inwardly rectifying potassium channels that are natively activated by G-protein coupled 
receptors (GPCRs) through interactions with Gβγ subunits.1 One of the most important 
effects of GIRK activation and subsequent channel opening is the hyperpolarization of cell 
membranes, which immediately results in a reduction of activity in excitable cells. 
Therefore, neurotransmitters that target both ion channels and GPCRs, including glutamate, 
γ-aminobutyric acid, acetylcholine, dopamine and serotonin, can have inhibitory affects. As 
a consequence, GIRK channels play crucial roles in cognition, nociception, coordination, 
energy homeostasis and cardiac output.2 Therefore, it is unsurprising that the malfunction of 
GIRK channels is associated with several neurological and cardiological disorders.3
GIRK channels are comprised of homo- or heterotetramers formed by the four subunits 
GIRK1-4.4 Although the expression patterns of GIRK subunits differs throughout the body, 
the prototypical GIRK channels of the central nervous system (CNS) are GIRK1/2 
heteromers and the isoforms found in the cardiovascular system are GIRK1/4 channels.5 
Recent breakthroughs in structural biology have identified the molecular basis for GIRK 
channel function, such as inward rectification and polyamine block, as well as intracellular 
activation by sodium ions and lipids.6
It has been demonstrated that GIRK channels are inhibited by a variety of drugs, as well as 
polyamines and barium ions.7 However, most of these compounds are not selective for 
GIRK channels.8,9 GIRK channels can also be activated by small molecules including 
volatile anesthetics,10 ethanol11 and the natural product naringin.12 Again these compounds 
either exhibit poor selectivity, poor potency or a combination of the two. However, the 
landscape of GIRK channel research was recently transformed by two small molecules, 
ML297 and VU0259369 (Fig. 1a).13 These compounds were shown to be the first potent 
and selective activators of GIRK channels bearing the GIRK1 subunit. Subtle changes to the 
molecular structure of ML297 resulted in the creation of potent GIRK1 channel inhibitors, 
an example of which is compound 1 (Fig. 1a).14
With the first small molecular agonists of GIRK channels at our disposal, we sought to 
develop photoswitchable versions that can endow light control to GIRK channels.15 This 
approach, termed photopharmacology, is able to confer exquisite spatiotemporal control onto 
biological systems using the unrivalled precision of light and has previously been used to 
optically control ion channels,16 GPCRs,17 enzymes18 and antibiotics.19
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Herein, we present LOGO (the Light Operated GIRK-channel Opener), an azobenzene 
photoswitch based on VU0259369 that endows GIRK channels with remarkable 
photocontrol using UV and blue light. LOGO is the first example of a photochromic K+ 
channel opener, as opposed to blocker,20 and the first photoswitch to selectively target GIRK 
channels. We envisage that LOGO will be a valuable tool for GIRK channel research, 
allowing the dissection of GIRK signaling from other GPCR dependent pathways. This will 
further our understanding of GIRK channel function and facilitate their development as a 
therapeutic target.
Results and Discussion
Using the compounds ML297 and VU0259369 as a basis for our photoswitch design, we 
employed an ‘azo-extension’ strategy to furnish our family of LOGOs (Fig. 1b).21 In the 
ML297 series, we prepared LOGO1-4 bearing different electron-donating groups in the 4′-
position of the azobenzene. In a similar fashion, LOGO5 and LOGO6 were derived from 
the compound VU0259369. The representative synthesis of LOGO5 started from sulfonyl 
chloride 2. Nucleophilic substitution with dimethylamine, followed by reduction of the 
aromatic nitro group, furnished sulfonamide 4 (Fig. 1c). An amide coupling reaction 
between 4 and 4-nitrophenylacetic acid (5) afforded nitro amide 6, which was then reduced 
to the aniline 7. Mills reaction of aniline 7 with nitrosobenzene (8) in the presence of acetic 
acid then afforded LOGO5. The synthesis of LOGO1-4 and LOGO6 proceeded in a similar 
fashion and is discussed in the supporting information (Fig. S1).
With our small library of LOGOs in hand, we set about determining their photoswitching 
properties using UV-Vis spectroscopy. From these experiments, we found the optimum 
wavelengths for the photoswitching of each of the compounds (Fig. S2). This information 
was then applied to our initial compound evaluation using patch clamp electrophysiology in 
HEK293T cells expressing GIRK1/2 channels (Fig. 2a). Beginning with LOGO1, we found 
that it could efficiently open GIRK1/2 channels as its trans-isomer. However, upon 
isomerisation to its cis-isomer using UV light (390 nm), only a small decrease of the current 
in the patch clamp experiment was observed. Based on these results, we postulated that 
LOGO2-4 would endow the GIRK channels with more light dependent current because of 
the increased steric interactions between the ligand-binding site of the GIRK channel and the 
substituents in the 4′-position of the azobenzene.
Although a small increase in the photoswitching of the GIRK channel was observed, it was 
still minor compared to the overall activation of the channel. We therefore turned our 
attention to LOGO5 and LOGO6, which were derived from VU0259369 instead of 
ML297. Pleasingly, we discovered that LOGO5 not only activates GIRK1/2 channels, but is 
an excellent photoswitch (Fig. 2a). We next evaluated the red-shifted photoswitch LOGO6, 
but to our surprise the photocurrent achieved was drastically reduced compared to that of 
LOGO5 (Fig. 2a). Therefore, our future investigations and biological evaluation focused on 
LOGO5. Overall, analysis of LOGO1-6 demonstrated that potent and efficacious ligands 
could be easily obtained by extending portions of known agonists (Fig. 1a) to include 
azobenzenes. By contrast, there is a narrow ‘structural window’ for photoswitchable 
agonists, that is compounds that dramatically change their efficacy upon light-isomerisation.
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Having determined that LOGO5 is our optimal photoswitch for the control of GIRK1/2 
channels, we investigated its properties in detail using patch clamp electrophysiology and 
NMR spectroscopy. Firstly, we established that in the dark LOGO5 (10 µM) is almost as 
efficacious as VU0259369 (10 µM). The same is true under blue light illumination, where 
trans-LOGO5 also predominates (Fig. 2b). Photoisomerisation using UV light (360 nm) 
then showed that cis-LOGO5 is considerably less active on GIRK1/2 channels (Fig. 2b and 
S3). Reversible photoactivation with LOGO5 is very robust, with no noticeable loss of 
photocurrent over several switching cycles in voltage-clamp mode (Fig. 2c). Highly 
reproducible photoswitching of LOGO5 was also obtained when operating in current-clamp 
mode (Fig. S4). Next we determined the action spectrum of LOGO5. When the wavelength 
was switched between blue light (440 nm) and different wavelengths of UV light (330–380 
nm), we observed large differences in current (Fig. 2d). The minimal inward current was 
observed at 360 nm, whereas illumination at 330, 340, 350 and 370 nm gave more inward 
current. This corresponds to the photostationary states (PSS) of LOGO5 in DMSO-d6 
solution as determined by 1H NMR spectroscopy (Fig. 2e). Here 100% cis-LOGO5 content 
was observed at 360 nm, whereas 370 and 380 nm etc. gave increasing trans-LOGO5 
content. Hence the concentration of active trans-LOGO5 can be controlled with the colour 
of the light (photodosing).22 The kinetics of LOGO5 activation were shown to be fast, with 
illumination at 440 nm for 1 second resulting in almost complete opening of the GIRK1/2 
channel (Fig. S6).
Next, we monitored the action of LOGO5 on GIRK1/2 channels expressed in HEK293T 
cells by elevating the holding potential in 10 mV steps from −100 mV to +50 mV. During 
each voltage step illumination was switched between 360/440/360 nm (Fig. 3a). Again, we 
found that the cis-isomer of LOGO5 has very little activity at GIRK1/2 channels, whilst the 
trans-isomer of LOGO5 shows strong GIRK1/2 activation. The amplitude of photocurrents 
at different holding potentials reflects the inward rectification of GIRK1/2 channels (Fig. 
3b). Given the high concentration of K+ ions (50 mM), the reversal potential was found to lie 
between −30 and −20 mV.
To evaluate the activity of LOGO5 at different GIRK channel subtypes, we next employed 
the thallium flux assay technique (Fig. 4).23 We found that LOGO5 is capable of activating 
GIRK channels that contain the GIRK1 subunit with similar potency and efficacy (GIRK1/2: 
EC50 = 1.2 ± 0.09 µM, %Emax = 95 ± 5.0; GIRK1/4: EC50 = 1.9 ± 0.10 µM, %Emax = 101.5 
± 6.4; Table S1). However, LOGO5 is unable to activate homodimeric GIRK2 channels, 
even at high concentrations.
Having demonstrated LOGO5 on HEK293T cells, which heterologously express GIRK1/2 
channels, we next wondered if this tool could be used to control excitable cells that natively 
express GIRK channels. To test this, we turned to dissociated rat hippocampal neurons 
which have been shown to express a variety of GIRK subunits.24 After the application of 
LOGO5 (20 µM), pyramidal neurons exhibited large membrane hyperpolarization (15.8 
± 2.5 mV, n=7 cells) in response to illumination with blue light (450 nm), which was 
reversed with UV light (360 nm) (Fig. S7a). Photoswitching of LOGO5 in both directions 
was stable in the dark over tens of seconds while in current-clamp mode (Fig. 5a) indicating 
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that constant illumination of the sample is not required. This bistability is characteristic of 
‘normal’ azobenzenes.25 In voltage-clamp mode at −60 mV, blue light (450 nm) illumination 
induced an outward current (50.3 ± 4.8 pA, n=4 cells), consistent with activation of a 
potassium conductance (Fig. S7b). Most importantly when at depolarised potentials, 
LOGO5 was able to reversibly silence action potential firing under blue light (450 nm) 
illumination (Fig. 5b). Illuminating with UV light (360 nm) restored action potential firing. 
The photoswitching of LOGO5 in dissociated rat hippocampal neurons was also highly 
reliable; photoswitching could be repeated for the entire length that a patch was maintained 
(~5–10 minutes; Fig. S7c), indicating that LOGO5 is a useful tool for experiments over 
extended periods of time.
With the control of native GIRK channels accomplished in rat hippocampal neurons, we 
investigated if LOGO5 had any effect in living animals. We selected zebrafish larvae (Danio 
rerio) as our organism of choice as they are transparent, enabling facile light delivery and 
they have previously been used in conjunction with biologically active compounds 
containing azobenzene photoswitches.26 Accordingly, zebrafish larvae 5–7 days post 
fertilisation were exposed to 10 second pulses of UV light (365 nm) and blue light (455 nm), 
in between interludes of ambient light (Fig. S8). After the first cycle of UV and blue light 
pulses the time that the zebrafish larvae spent swimming in the 10 seconds after the light 
pulse was measured to give the background swimming behaviour. The zebrafish larvae were 
then incubated with LOGO5 (50 µM) for 1 hour and the same protocol was used to 
determine the effect of the photochromic GIRK agonist by calculating the change in 
swimming time. Gratifyingly, the zebrafish larvae showed significantly different changes in 
swimming time in the presence of LOGO5, which could be modulated by alternating 
illumination with UV and blue light (Fig. 6). When illuminated with blue light, the zebrafish 
larvae exhibited reduced swimming times compared to the control experiments. After 
illuminating with UV light for 10 seconds, the zebrafish larvae dramatically increased the 
time they spent swimming. However, the zebrafish larvae also showed increased swimming 
time in the control experiment using only UV light. To dissect the effect of LOGO5 from 
the native response to UV light, we performed additional experiments using the non-
photoswitchable GIRK activator ML297 (Fig. 6). These experiments demonstrated that 
there is almost no change in the swimming behaviour of the zebrafish larvae when 
illumination is switched between UV and blue light. This is in stark contrast to the results 
obtained using LOGO5 and UV light.
Conclusion
In summary, we have developed a photochromic agonist that enables the optical control of 
GIRK channels. Our photoswitch, LOGO5, is active as its trans-isomer, with UV light 
illumination converting it to its significantly less active cis-isomer. LOGO5 has been shown 
to work with GIRK channels that bear the GIRK1 subunit and can be used to efficiently 
reduce neuronal excitability in dissociated hippocampal neurons in a light dependent 
manner. LOGO5 can also be implemented in vivo, for instance in zebrafish larvae. Future 
work is focused on the advanced development of LOGO5 as an optical tool to control GIRK 
channels in higher animals.
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Fig. 1. 
Design of the photoswitchable GIRK channel agonists LOGO1-6 using an ‘azo-extension’ 
strategy. a) Chemical structures of the GIRK channel agonists ML297 and VU0259369, and 
the GIRK channel inhibitor 1. b) Chemical structures of the photoswitchable GIRK agonists 
LOGO1-6. c) Synthesis of LOGO5 using a Mills reaction.
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Fig. 2. 
Whole-cell patch clamp electrophysiology of HEK293T cells expressing GIRK1/2 channels. 
a) Evaluation of LOGO1-6 (1 µM) revealed that LOGO5 displayed the best photoswitching 
behaviour. b) LOGO5 (10 µM) is almost as efficacious as VU0259369 (10 µM) in the dark 
and under blue light (440 nm) illumination (n=4 cells). c) The photoswitching of LOGO5 
was shown to be reversible over many switching cycles in voltage-clamp mode. d) Action 
spectrum of LOGO5 (1 µM) showing the accurate control of cellular currents by toggling 
the illumination wavelength between 440 nm and 330–380 nm. e) Photoswitching of 
LOGO5 in DMSO-d6 solution using 1H NMR spectroscopy (see ESI for details). Values 
represent mean ± SEM.
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Fig. 3. 
Inward rectification of GIRK1/2 channels in the presence of LOGO5 (10 µM) in voltage-
clamp mode. a) The holding potential was elevated in 10 mV steps from −100 mV to +50 
mV illuminating with 360/440/360 nm at each step to give the cis-isomer of LOGO5 (360 
nm) and the trans-isomer of LOGO5 (440 nm). Respective peak currents are indicated as 
grey and blue circles. b) Averaged photocurrent amplitudes (ΔI = I trans-LOGO5 – I cis-
LOGO5). Inward rectification is also translated into the photocurrents ΔI (n=3 cells). Values 
represent mean ± SEM.
Barber et al. Page 10
Chem Sci. Author manuscript; available in PMC 2017 January 13.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig. 4. 
Potency, efficacy and selectivity of LOGO5. Shown are fits to representative data obtained 
from testing multiple concentrations of LOGO5 on cell lines stably expressing GIRK1/2 
(blue circles), GIRK1/4 (green triangles) and GIRK2 (red squares). The measured potencies 
for GIRK1/2 and GIRK1/4 were 1.2 ± 0.09 µM and 1.9 ± 0.1 µM, respectively. LOGO5 was 
inactive on cells that only express GIRK2. Efficacy values were normalised to the maximum 
activity observed using ML297 (10 µM) on GIRK1/2-expressing cells. Error bars represent 
± SEM obtained from triplicate wells. Reported potency values represent the SEM obtained 
from three independent experiments.
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Fig. 5. 
Optical control of excitability via endogenous GIRK channels using LOGO5 in rat 
hippocampal neurons. a) Photoswitching of LOGO5 reversibly and repeatedly manipulated 
membrane potentials by 10–20 mV. Light responses were stable in the dark for tens of 
seconds due to the slow relaxation of the cis- and trans-isomers of LOGO5. b) 
Photoswitching of LOGO5 results in the control of spontaneous action potential firing. 
(grey = 360 nm; blue = 450 nm).
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Fig. 6. 
Optical control of zebrafish motility in the presence of LOGO5. After the application of 
LOGO5 (50 µM), the swimming behaviour of the zebrafish larvae was reduced under blue 
light illumination and increased under UV light illumination when compared to the control 
(1% DMSO) zebrafish. Experiments using the non-photoswitchable GIRK opener ML297 
(50 µM) showed reduction of the zebrafish motility independent of UV and blue light 
illumination. (LOGO5 n=36 zebrafish; ML297 n=36 zebrafish; control (1% DMSO) n=72 
zebrafish) (*P < 0.01 versus control 365 nm; **P < 0.001 versus control 455 nm). Values 
represent mean ± SEM.
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Optical control of GIRK channels using visible
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G-protein coupled inwardly rectifying potassium (GIRK) channels
are an integral part of inhibitory signal transduction pathways,
reducing the activity of excitable cells via hyperpolarization. They
play crucial roles in processes such as cardiac output, cognition
and the coordination of movement. Therefore, the precision
control of GIRK channels is of critical importance. Here, we
describe the development of the azobenzene containing molecule
VLOGO (Visible Light Operated GIRK channel Opener), which acti-
vates GIRK channels in the dark and is promptly deactivated when
illuminated with green light. VLOGO is a valuable addition to the
existing tools for the optical control of GIRK channels as it
circumvents the need to use potentially harmful UV irradiation. We
therefore believe that VLOGO will be a useful research tool for
studying GIRK channels in biological systems.
Introduction
G-protein coupled inwardly rectifying potassium (GIRK) chan-
nels are a family of potassium channels that are opened via
interactions with Gβγ protein complexes.1 Upon channel
opening, GIRK channels hyperpolarize cell membranes causing
a reduction in the activity of excitable cells. Therefore, GIRK
channels are involved in processes such as nociception, cogni-
tion and cardiac output2 and are associated with numerous
neurological and cardiovascular conditions.3
GIRK channels exist as either homo- or heterotetramers
comprised of the four subunits GIRK1-4, which exhibit distinct
expression patterns throughout the body.4 For example,
GIRK1/2 channels are typically found in the central nervous
system (CNS) and GIRK1/4 channels are characteristic of the
cardiovascular system.5 It has been shown that GIRK channels
are activated by a variety of small molecules, albeit with
varying degrees of selectivity.6 The compounds ML297 and
VU0259369 are exceptions as they are potent and selective acti-
vators of GIRK channels bearing the GIRK1 subunit (Fig. 1a).7
We recently demonstrated that GIRK channels can be
endowed with light control using photopharmacology.8 Our
freely diﬀusible photoswitch LOGO, is a derivative of
VU0259369 that contains an azobenzene moiety as the photo-
responsive element (Fig. 1a).9 It harnesses the precision of
light to accurately control the spontaneous action potential
firing of dissociated hippocampal neurons and the swimming
behaviour of zebrafish larvae. However, a significant drawback
of LOGO is that UV and blue light are required for its cis/trans
photoisomerisation. This results in increased levels of photo-
toxicity10 and limits the amount of tissue penetration.11 By
employing photoswitches that respond to red-shifted wave-
lengths of light we would be able to improve these
properties.12
Herein, we present VLOGO (Visible Light Operated GIRK
channel Opener), which is an ortho-fluorinated azobenzene
photoswitch that enables the optical control of GIRK channels
using violet and green light. The red-shifted properties of
VLOGO improve its suitability for experiments in vivo and we
therefore envisage that VLOGO will be a valuable tool for GIRK
channel research.
Results and discussion
Many methods can be employed to create azobenzene photo-
switches that isomerise using visible light.13 One of the sim-
plest methods is to increase the electron density of the azo-
benzene moiety by incorporating electron-donating groups in
its para-position.14 We initially investigated this avenue by pre-
paring a series of photoswitchable GIRK channel openers (1–4)
†Electronic supplementary information (ESI) available: Experimental procedures
and characterisation data. See DOI: 10.1039/c6ob02153k
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that had electron-donating groups in the 4′-position of the azo-
benzene (Fig. 1b). This was achieved by forming the di-
azonium salt of an intermediate aniline and trapping it with a
range of electron rich aromatic compounds (Fig. S1†). More
recently, several research groups have shown that exchanging
the ortho-positions of the azobenzene with halogen substi-
tuents can create photoswitches that undergo cis/trans isomeri-
sation when exposed to long wavelength visible light.15 We
therefore became interested in preparing GIRK channel
openers bearing ortho-fluoro and ortho-chloro substituted
azobenzenes. An amide coupling between aniline 7 and acid 8
furnished amide 9, which was subsequently reduced in the
presence of palladium on carbon to aﬀord difluoro aniline 10.
A Mills reaction between difluoro aniline 10 and difluoro
nitrosobenzene 11 furnished VLOGO in a moderate 30% yield
(Fig. 1c). In contrast, the ortho-chloro azobenzene 6 was syn-
thesised using a recently reported C–H activation strategy
(Fig. S1†).16
With our small library of compounds in hand, we deter-
mined their optimum photoswitching properties using UV-Vis
spectroscopy (Fig. S2†). We then applied this information to
our initial compound analysis using patch clamp electro-
physiology of GIRK1/2 channels expressed in HEK293T cells
(Fig. 2a). Starting with the 4′-substituted azobenzenes 1–4
(Fig. 2a), we observed small amounts of GIRK1/2 channel
opening and moderate levels of current modulation upon
photoswitching with the 4′-amino azobenzene 2 and the 4′-N,
N-diethyl azobenzene 3. In contrast, almost no change in
current was observed upon photoswitching using azobenzenes
1 and 4. We next evaluated VLOGO and found it to be an excel-
lent photoswitchable opener of GIRK1/2 channels using 400
and 500 nm light (Fig. 2a). Spurred on by this result we
assessed ortho-chloro azobenzene 6. However, we discovered
that this photoswitch could not endow GIRK1/2 with signifi-
cant amounts of light control. This was an unfortunate result,
as azobenzene 6 would have allowed longer wavelengths of
light to be used for the optical control of GIRK channels.
When examining all of the results, it becomes clear that only
small modifications to the azobenzene photoswitch are toler-
ated in order to retain both potent agonism and good photo-
switching behaviour at GIRK1/2 channels.
With ortho-fluoro azobenzene VOLOGO identified as our
optimal red-shifted photoswitch for GIRK1/2 channels, we
further investigated its properties using patch clamp electro-
physiology. Firstly, we investigated the action spectrum of
VLOGO by switching the wavelength between violet light
(400 nm) and diﬀerent wavelengths of blue/green light
(440–540 nm), we observed large diﬀerences in current
(Fig. 2b). The minimal inward current was exhibited when illu-
minating at 500 nm. In contrast, 440, 460, 480, 520 and
540 nm resulted in more inward current (Fig. S3†). We then
established that reversible photoactivation of VLOGO (10 μM)
is very robust, with almost no loss of photocurrent over many
switching cycles (Fig. 2c). The trans-isomer of VLOGO, which
Fig. 1 Design of the red-shifted photoswitchable GIRK channel agonists 1–6. (a) Chemical structures of the GIRK channel agonists ML297 and
VU0259369, and the photoswitchable GIRK channel agonist LOGO. (b) Chemical structures of the red-shifted GIRK channel agonists 1–6. (c)
Synthesis of VLOGO using a Mills reaction.
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predominates in the dark and under violet light (400 nm) illu-
mination, is the most active form of VLOGO. Upon photo-
isomerisation using green light (500 nm), the considerably
less active cis-isomer of VLOGO is formed, causing a reduction
in the observed current. When operating in current clamp
mode the photoswitching of VLOGO was also found to be
highly reproducible (Fig. S4†). Lastly, we examined the stability
of cis-VLOGO in the dark (Fig. 2d). After the full cis-isomer
content had been reached under 500 nm light illumination,
VLOGO was exposed to dark conditions, quickly resulting in
increased inward current. The minimal inward current was
achieved again using 500 nm light. This result demonstrates
that constant illumination of VLOGO is required to maintain
the maximum cis-isomer content.
Having characterised VLOGO using patch-clamp electro-
physiology in HEK293T cells, we subsequently evaluated the
activity of VLOGO towards diﬀerent GIRK channel subtypes
using the thallium flux assay technique (Fig. 3).17 We found that
VLOGO activates GIRK channels containing the GIRK1 subunit,
whilst not aﬀecting homodimeric GIRK2 channels. VLOGO exhi-
bits similar potency at GIRK channels (GIRK1/2: EC50 = 2.0 ±
0.11 μM; GIRK1/4: EC50 = 1.9 ± 0.06 μM) as the non-substituted
photoswitchable GIRK channel agonist LOGO.9 However, the
eﬃcacy of VLOGO is significantly reduced (GIRK1/2: %Emax =
49.4 ± 4.7; GIRK1/4: %Emax = 30.9 ± 5.2).
After demonstrating that VLOGO can optically control cellu-
lar currents in HEK293T cells heterologously expressing
GIRK1/2 channels, we next investigated if it could be used to
Fig. 2 Whole-cell patch clamp electrophysiology of HEK293T cells expressing GIRK1/2 channels. (a) Evaluation of compounds 1–6 (10 μM) revealed
that VLOGO displayed the best photoswitching behaviour (n = number of experiments). (b) Action spectrum of VLOGO (10 μM) showing the precise
control of HEK293T cell currents by toggling the illumination wavelength between 400 nm and 440–540 nm. (c) Reversible photoswitching of
VLOGO (10 μM) recorded in voltage-clamp mode. (d) Observed current increase when no light stimulus is applied to the cis-isomer of VLOGO. Error
bars represent mean ± SEM.
Fig. 3 Potency, eﬃcacy and selectivity proﬁle of VLOGO. Shown are ﬁts
to representative data obtained from testing multiple concentrations of
VLOGO on cell lines stably expressing GIRK1/2 (blue circles), GIRK1/4
(green triangles) and GIRK2 (red squares). The measured potencies for
GIRK1/2 and GIRK1/4 were 2.0 ± 0.11 μM and 1.9 ± 0.06 μM, respectively.
Eﬃcacy values were normalised to the maximum activity observed using
ML297 (10 μM) on GIRK1/2-expressing cells. Error bars represent mean ±
SEM obtained from triplicate wells. Reported potency values represent
the mean ± SEM obtained from three independent experiments.18
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control GIRK channels in excitable cells.19 For this endeavour
we conducted electrophysiological experiments on
CA1 hippocampal neurons found in acute brain slice pre-
parations from wild type mice. Firstly, we recorded current–
voltage (I–V) relationships comparing the control traces with
those obtained in the presence of VLOGO (Fig. 4a). Due to the
inwardly rectifying nature of GIRK channels, we would expect
to see increasing amounts of inward current as the voltage
becomes more negative. After the application of VLOGO
(100 μM) and subsequent wash out, the hippocampal neuron
exhibited increasing inward current at voltages lower than
−90 mV during a −120 mV to +30 mV voltage ramp. This is
indicative of GIRK channel opening.7 Most importantly
VLOGO was able to reversibly silence spontaneous action
potential firing under violet light (400 nm) illumination when
the hippocampal neurons were held at depolarised potentials
(Fig. 4b). Changing the illumination wavelength to 500 nm
then eﬃciently restored the action potential firing.
After accomplishing the control of native GIRK channels in
mouse hippocampal neurons using VLOGO, we investigated if
it could be used to optically control the movement of living
animals. For these experiments we selected zebrafish larvae
(Danio rerio) as light can easily be delivered to them due to
their transparency.20 Accordingly, zebrafish larvae 5–7 days
post fertilisation were exposed to 2 minute intervals of alter-
nating violet light (420 nm) and green light (520 nm)
(Fig. S5†). After the first cycle of violet and green light, the dis-
tance (mm) that the zebrafish larvae moved in a 10 second
time period within a representative section of each 2 minute
interval was measured to give the background swimming be-
haviour for each condition. The zebrafish larvae were then
incubated with VLOGO (100 μM) for 1 hour and the same pro-
tocol was used to determine its eﬀect by calculating the
change in swimming distance. Pleasingly, the zebrafish larvae
showed significantly diﬀerent swimming distances in the pres-
ence of VLOGO, which could be modulated by changing the
illumination from violet to green light (Fig. 5). The zebrafish
larvae exhibited reduced swimming distances when illumi-
nated with violet light compared to the control zebrafish. After
illuminating with green light for a total of 2 minutes, the
swimming distance of the zebrafish was not significantly
diﬀerent from the control experiment. We then performed
additional experiments using the non-photoswitchable GIRK
activator ML297 in an eﬀort to dissect the eﬀect of VLOGO
from the native responses to violet and green light. These
experiments confirmed that there is almost no change in the
swimming distances of zebrafish larvae when illumination is
changed between violet and green light. This is significantly
diﬀerent from the results obtained using VLOGO in conjunc-
tion with violet and green light.
Conclusion
In summary, we have developed a photochromic compound
that enables the optical control of GIRK channels using visible
light. The photoswitch, VLOGO, is transiently active in the
Fig. 4 Optical control of cell excitability in mouse hippocampal
neurons. (a) Current–voltage (I–V) relationships indicative of GIRK chan-
nels. Black; current–voltage relationship of control neuron (n = 3 cells).
Red; current–voltage relationship of VLOGO mediated currents under
ambient light conditions (n = 4 cells). All recordings were conducted in
the presence of tetrodotoxin (TTX) (1 μM) using −120 mV to +30 mV
voltage ramp over 3 seconds and residual potassium currents were sub-
tracted from the ramp recording. (b) Photoswitching of VLOGO in
current clamp mode enables the optical control of spontaneous action
potential ﬁring. Error bars represent mean ± SEM.
Fig. 5 Optical control of zebraﬁsh motility in the presence of VLOGO.
After the application of VLOGO (100 μM), the swimming activity of the
zebraﬁsh larvae was reduced under violet light (420 nm) illumination
and back to baseline under green light (520 nm) illumination when com-
pared to the control (1% DMSO) zebraﬁsh. Experiments using the non-
photoswitchable GIRK opener ML297 (100 μM) showed reduction of the
zebraﬁsh motility independent of violet and green light illumination.
(VLOGO n = 18 zebraﬁsh; ML297 n = 15 zebraﬁsh; control (1% DMSO)
n = 15 zebraﬁsh) (* n.s. versus control 520 nm; **P < 0.001 versus
control 420 nm); ***P < 0.001 versus control 520 nm). Error bars re-
present mean ± SEM.
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dark and when illuminated with violet light. Green light illu-
mination then rapidly converts it to its significantly less active
cis-isomer. We have demonstrated that VLOGO opens GIRK
channels bearing the GIRK1 subunit and that it can be used to
optically reduce neuronal excitability in dissociated hippocam-
pal neurons. VLOGO also exhibits in vivo activity, controlling
the motility of zebrafish larvae in a light dependent manner.
Future work is concentrated on the development of VLOGO as
a tool for the optical control of GIRK channels in higher
animals.
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  2   
Abstract 
 
The zebrafish is increasingly being employed as an experimental platform to 
model neuropsychiatric diseases and to screen for novel neuro-active 
compounds. While the superb genetic and optical access that this system offers 
has long been recognized, these features have not been fully exploited to 
investigate disease mechanisms and possible therapeutic interventions. Here we 
introduce a light-sheet imaging and graph-theoretical analysis pipeline to 
determine the effects of the known or suspected antidepressant compounds 
fluoxetine, ketamine and cycloserine on brain-wide neural activity patterns. We 
imaged the brains of both wildtype fish and grs357 mutants, which harbor a 
missense mutation that abolishes glucocorticoid receptor (GR) transcriptional 
activity. The grs357 mutation results in a chronically elevated stress axis together 
with behavioral endophenotypes of depression. Consistent with broad expression 
of the glucocorticoid receptor throughout the brain, we show that the mutant 
fish exhibit an altered correlational structure of resting-state brain activity. 
Intriguingly, in gr s357 mutant fish, an increased ‘modularity’, which represents 
the degree of segregation of the network into highly clustered modules, was 
restored by acute fluoxetine administration to wildtype levels. Ketamine and 
cycloserine also normalized specific parameters of the graph. Fluoxetine altered 
network function in the same direction in mutant and wildtype, while ketamine 
and cycloserine had effects that were opposite for the two genotypes. We propose 
that light-sheet imaging, followed by graph analysis, is a content-rich and 
scalable first-pass approach for studying the neural consequences of drug effects 
and drug x genotype interactions in zebrafish models of psychiatric disorders.  
  
 3 
Introduction 
Recent work has highlighted the promise of the zebrafish model to understand 
mutations in psychiatric disease genes and drug actions (for a review, see Haesemeyer 
& Schier, 2015). Zebrafish larvae carrying a mutation of the GR (grs357) have a 
chronically elevated hypothalamic-pituitary-adrenal (HPA) axis due to disruption of 
negative feedback via cortisol (Fig. 1a). The grs357 mutants swim less and startle more 
than wildtype siblings at larval stages. When repeatedly placed into a novel tank, 
adult mutants fail to habituate and rather exaggerate their behavioral response 
('freezing') to this mild stressor. Importantly, their HPA activation and behavior can 
be normalized by acute or chronic treatment with the selective serotonin reuptake 
inhibitor (SSRI) fluoxetine (Griffith et al., 2012; Ziv et al., 2013). Moreover, it has 
been shown that reducing HPA axis activity and enhancing serotonergic transmission 
via treatment with fluoxetine shifts neuronal responses and processing of food stimuli 
in the fish (Filosa et al., 2016). One of our goals therefore was to evaluate the 
potential of fluoxetine to restore altered brain function. 
In addition to fluoxetine, we investigated ketamine and cycloserine, two 
potential antidepressant compounds with different mechanisms of action. Ketamine is 
a rapid-acting N-methyl-D-aspartate (NMDA) receptor antagonist and has recently 
been approved by the US Food and Drug Administration (FDA) as a nasal spray for 
the treatment of SSRI-resistant depression. Ketamine has also been shown to 
modulate zebrafish behavior (Michelotti et al., 2018), although its range of actions in 
this model system is poorly understood. Cycloserine is a natural antibiotic product 
of Streptomyces orchidaceus and Streptomyces garyphalus and has been employed in 
tuberculosis therapy since the late 1950s (Offe, 1988). Years later it was postulated, 
and later proven in slice preparations, that the compound influences long-term 
potentiation, a neuronal mechanism thought to be relevant for learning (Watanabe et 
al., 1992). Cycloserine is a partial NMDA agonist (Watson et al., 1990); in vivo, it 
acts like an agonist at low doses, but has antagonistic features at high doses. Its 
potential for the treatment of neurological and psychiatric conditions, such as major 
depression, is currently being investigated. 
Here we used light-sheet calcium imaging for recording of spontaneous brain-
wide activity in zebrafish (Ahrens et al., 2013) and analyzed the correlational 
 4 
structure of the data with a computational platform based on graph theory. This 
approach was inspired by work in human functional magnetic resonance imaging 
(fMRI; Ye et al., 2015), which employs voxel-based graphs to reveal global patterns 
of brain activity. Recording of tens of thousands of single-cell activity traces 
generates a deluge of data, and we reasoned that graph analysis offers a relatively 
straightforward method to extract informative statistical parameters from the resulting 
adjacency matrix. Using a similar graph-based approach, albeit with far fewer nodes, 
Avitan et al. (2017) studied the developmental reorganization of spontaneous activity 
in the tectum. We compared whole-brain functional connectivity in wildtype and 
grs357 mutants and detected genotype-linked differences. Finally, we showed that, in 
line with normalizing grs357 behavior (Griffith et al., 2012; Ziv et al., 2013), acute 
fluoxetine administration restored disrupted network parameters in the mutant fish. 
Ketamine and cycloserine also differentially affected specific parameters of whole-
brain functional connectivity. Our experimental workflow, light-sheet imaging 
followed by first-pass graph analysis, represents a content-rich, sensitive and scalable 
method to explore genetic and pharmacological alterations of brain-wide network 
activity in larval zebrafish. 
 
Results and Discussion 
Light-sheet imaging of resting-state brain activity in larval zebrafish  
To record spontaneous (resting state) whole-brain activity, we embedded mutant 
and wildtype zebrafish larvae, at 6 days post fertilization (dpf), in low-melting 
agarose gel. The animals carried the transgene Tg(elavl3:H2B-GCaMP6s), encoding a 
nuclear-localized GCaMP6s under the control of a pan-neuronal promoter (Fig. 1d, e). 
For each condition, eight grs357 mutants and eight wildtype fish were imaged at 
cellular-resolution with a custom-built light-sheet microscope, as described in 
Methods. Data were acquired in 5 min whole-brain recordings at 2 Hz, resulting in 
600 scanned volumes at baseline and after incubation with fluoxetine (20µM), 
ketamine (20µM) and cycloserine (20µM) for 1.5h and 3h in each fish (Fig. 1b). The 
concentration of 20µM was chosen to approximate the conditions of small-molecule 
compound screens in zebrafish larvae (Rihel et al., 2010; Kokel & Peterson, 2011). A 
 5 
recording time of 5 min was chosen to simulate measurements of resting-state brain 
activity by fMRI for functional connectivity analysis in human subjects with major 
depression (Greicius et al., 2007). We reasoned that this time window should be long 
enough to capture the normally occurring cycles of spontaneous brain activity in 
zebrafish. Although not tested systematically, drug incubation longer than 3h, or more 
frequent recordings within the 3 hour time window, appeared to result in inconsistent 
results, probably caused by stress, drug toxicity, photo-damage in the light-sheet 
microscope, or combinations thereof. Examples of motion-corrected, but otherwise 
raw fluorescence signals from single imaging planes are provided in two 
supplementary movies (Suppl. Movies M1 and M2: mutant and wildtype). 
Segmentation of brain-wide functional imaging data at single-cell resolution 
To examine functional connectivity, four-dimensional imaging stacks (time, x, 
y, z) were split into time series of single planes and corrected for motion artefacts 
using a customized version of the CaImAn package (Pnevmatikakis et al., 2017; 
Giovannucci et al., 2019) (see Methods). Regions of interest (ROIs) were spatial 
clusters of co-active pixels, likely corresponding to single neurons (Fig. 1f, g) 
(Portugues et al., 2014). The CaImAn algorithm picked up between 20,000 and 
40,000 cells for each fish brain, i. e., ca 25% of all neurons. A subset of them, 10,000 
ROIs were selected randomly for further analysis of network properties (Fig. 1g). 
Subsampling and this reduction in the number of cells analyzed reduced the 
computational load, and thus CPU time, generated by the high-dimensional 
connectivity matrix by two orders of magnitude (100 Million vs. 1600 Million matrix 
components) without noticeably affecting the statistics of the overall network 
structure, e.g. the degree distribution for different numbers of subsampled neurons 
(Fig. 2). Functional connectivity was computed as Pearson’s correlation coefficients 
between ∆F/F signal time series of these ROIs (Fig. 1h).  
Analysis of functional imaging data by graph analysis 
A powerful way to describe the functional organization of the whole brain is 
to treat the brain network as a graph. A graph is defined as a mathematical object 
consisting of a set of items, called nodes, and pairwise relationships between them, 
called edges (Bollobas, 1998). In our datasets, nodes were defined as the 104 
 6 
randomly selected cells (ROIs), and edges were defined by calculating Pearson 
correlation coefficients between ROI signal time courses. Hence, the entirety of all 
edges was represented by a 104 × 104 correlation matrix (Fig. 1h). Because edges 
from a node to itself are not allowed in simple graphs, the diagonal of each matrix 
was set to zero and the matrix was thresholded at 0.25, in order to ignore negative 
edges and remove spurious connections. The threshold of 0.25 was not tested 
systematically but is commonly used for such analysis because results are not 
particularly sensitive to the precise value of the threshold chosen. Interactions 
between network nodes are best described by weighted connections, where the weight 
indicates the score of correlation and strength of interaction between nodes. Thus, a 
weighted connectivity matrix was derived to extract neural assemblies from the 
recordings (see Methods).  
Many studies have focused on local properties of networks, such as clustering 
(Watts & Strogatz, 1998), degree distributions (Barabasi & Albert, 1999; Amaral et 
al., 2000) and correlations (Pastor-Satorras et al., 2001; Newman, 2002). There have 
also been studies that examine large-scale properties such as path lengths (Watts & 
Strogatz, 1998), percolation (Cohen et al., 2000; Callaway et al., 2000) or hierarchy 
(Ravasz & Barabasi, 2003; Clauset et el., 2008). For our study, we chose the 
following standard metrics (Box 1): 1) clustering coefficient, 2) characteristic path 
length, 3) modularity and 4) small-worldness.   
Differences in functional connectivity between grs357 mutants and wildtype 
We explored genotype differences in the dataset after incubation with DMSO in 
the control condition (Fig. 3). Due to deviations of the data from a normal distribution 
according to Shapiro Wilk test statistics, non-parametric testing with the Mann-
Whitney U test was performed and the α-level was Bonferroni corrected according to 
multiple comparisons. The clustering coefficient (Fig. 3a), characteristic path length 
(Fig. 3c) and small-worldness (Fig. 3d) were not significantly different between grs357 
mutant and wildtype fish at baseline (p > 0.05). However, modularity (Fig. 3b) was 
significantly higher in the grs357 mutant fish (p = 0.007). In an intermediate step of 
calculating modularity, ROIs were assigned to distinct modules. ROIs that were 
grouped together within one module based on the calculation were extracted and 
color-coded to visualize their anatomical location.  
 7 
Mapping back the ROIs of detected modules to individual fish brains revealed 
that the number of modules in grs357 mutant fish was significantly greater compared to 
wildtype fish at baseline (Fig. 4a, b) (p = 0.034). These results suggest that the 
functional organization of the mutant brain comprises a greater number of relatively 
more isolated communities of neurons that seem to be diversely distributed across the 
brain (Fig. 4b). In wildtype fish the modules seem to be rather separated and located 
in distinct regions, with the forebrain comprising one module and a second module 
being located in the hindbrain (Fig. 4a). After 1.5h in the setup and incubation with 
DMSO, the clustering coefficient was significantly lower in the grs357 mutant 
compared to the wildtype fish (p = 0.005). The same holds true for small-worldness in 
the brain network (p = 0.001). The characteristic path length was significantly higher 
in the grs357 mutant fish compared to wildtype (p = 0.029). After incubation for 3h, 
genotype differences were present in all variables. Clustering and small-worldness 
were significantly lower in the grs357 mutant fish compared to wildtype (p = 0.001; p 
< 10-5), while characteristic path length and modularity were significantly (p = 0.011; 
p = 0.008) increased. These results suggest that time spent in the setup seems to 
differentially affect mutant and wildtype fish. Whilst the mutant fish have a 
chronically elevated stress level, wildtype fish might naturally respond to the stress 
experienced during the experimental procedure, which in turn affect network 
properties. A change in network parameters observed in wildtype, while absent in 
mutants, may imply a ceiling effect of the stress axis on functional connectivity in the 
grs357 brain.  
Normalization of brain-wide connectivity in the grs357 mutant by fluoxetine 
We hypothesized that acute fluoxetine administration might restore network 
connectivity in grs357 fish. Indeed, we observed that clustering (p = 0.125), 
characteristic path length (p = 0.171), modularity (p = 0.476) and small-worldness (p 
= 0.076) were no longer significantly different between fluoxetine-treated mutant and 
(DMSO-treated) wildtype brains. The same holds true for incubation over 3h, where 
there is no difference in clustering (p = 0.492), characteristic path length (p = 0.303), 
modularity (p = 0.090), number of modules (p = 0.473) (Fig. 3c) and small-worldness 
(p = 0.235). We propose that acute fluoxetine treatment has the potential to restore 
whole-brain functional organization of the mutant fish brain, an effect that may 
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explain the normalizing effect on behavior observed in our earlier study (Griffiths et 
al., 2012).  
When comparing drug effects, we observed that fluoxetine affects all network 
parameters, albeit not all of them with statistical significance, in the same direction 
for both genotypes. Incubation with fluoxetine for 3h increased clustering in mutants 
and wildtype (Fig. 3a; GR DMSO vs. GR fluoxetine: p < 10-5; WT DMSO vs. WT 
fluoxetine: p = 0.085), decreased characteristic path length (Fig. 3c; GR DMSO vs. 
GR fluoxetine: p = 0.016; WT DMSO vs. WT fluoxetine: p = 0.091), and increased 
small-worldness (Fig. 3d; GR DMSO vs. GR fluoxetine: p = 0.001; WT DMSO vs. 
WT fluoxetine: p = 0.165). Modularity was not significantly different between 
genotypes after 3h incubation (Fig. 3b; GR DMSO vs. GR fluoxetine: p = 0.197; WT 
DMSO vs. WT fluoxetine: p = 0.165). We conclude that there is little, if any, drug x 
genotype interaction (Table 1), and the direction of fluoxetine’s effect on whole-brain 
functional connectivity is independent of the animal’s chronic stress level.  
Restoration of clustering in grs357 mutants by ketamine 
After 1.5h of incubation with ketamine (20µM), clustering (Fig. 5a) was 
significantly reduced in grs357 mutants compared to wildtype control (p = 0.002). The 
characteristic path length (Fig. 5c) was increased (p = 0.005), modularity (Fig. 5b) 
was not significantly different (p = 0.109), and small-worldness (Fig. 5d) was reduced 
(p = 0.002). After incubation for 3h, there was no difference in clustering (p = 0.166), 
but modularity and characteristic path length were significantly higher in the ketamine 
treated grs357 fish compared to wildtype control (p = 0.038; p = 0.047). Small-
worldness was significantly reduced in the mutant brain network (p = 0.033). These 
results suggest that clustering is the network parameter most affected by treatment 
with ketamine. Since brain networks of ketamine-treated grs357 mutants show similar 
clustering as wildtype, we conclude that ketamine reduces segregation and thus 
enhances the efficiency of local information transfer in the mutant brain. This may be 
the functional correlate of reduced inhibition in the brain by ketamine acting as an 
NMDA receptor antagonist. 
Interestingly, ketamine differentially affected the two genotypes (Fig. 5). The 
Kruskal-Wallis test showed that there was a statistically significant difference in 
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network parameters between genotypes and drug treatments. Significant effects, e.g. 
for clustering (Chi square = 50.32, p < 10-5, df = 9) were further explored using post-
hoc testing. After incubation for 1.5h with ketamine, clustering (Fig. 5a; GR DMSO 
vs. GR ketamine: p = 0.019) was significantly reduced in grs357 mutants, while 
characteristic path length (Fig. 5c; GR DMSO vs. GR ketamine: p = 0.049) was 
increased. In wildtype, clustering (Fig. 5a; WT DMSO vs. WT ketamine: p = 0.006) 
and small-worldness (Fig. 5d; WT DMSO vs. WT ketamine: p = 0.003) were 
significantly reduced after incubation with ketamine compared to the wildtype DMSO 
control, while characteristic path length (Fig. 5c; WT DMSO vs. WT ketamine: p = 
0.023) was increased. After 3h incubation with ketamine, we observed higher 
clustering (Fig. 5a; GR DMSO vs. GR ketamine: p = 0.026) and increased small-
worldness (Fig. 5d; GR DMSO vs. GR ketamine: p = 0.043) in ketamine-treated grs357 
mutant fish compared to the grs357 mutant DMSO control. In wildtype fish, 
differences appeared in all network parameters after 3h incubation with ketamine 
compared to wildtype DMSO control: Clustering (Fig. 5a; WT DMSO vs. WT 
ketamine: p = 0.001) and small-worldness (Fig. 5d; WT DMSO vs. WT ketamine: p = 
0.000) were significantly reduced, whereas characteristic path length (Fig. 5c; WT 
DMSO vs. WT ketamine: p = 0.002) and modularity (Fig. 5b; WT DMSO vs. WT 
ketamine: p = 0.001) were increased. Thus, we observed a drug x genotype interaction 
effect (Table 1): Ketamine seems to increase functional connections and efficiency of 
global and local integration in the mutant. The opposite effect was observed in 
wildtype fish, where ketamine reduced both clustering and small-world properties of 
the neuronal network.  
Restoration of brain network function in grs357 mutants by cycloserine 
Cycloserine is an NMDA receptor agonist at low and an NMDA antagonist at 
high dosages. After 1.5h incubation with cycloserine, statistical tests revealed that 
there was no significant difference in clustering (p = 0.160) (Fig. 6a), characteristic 
path length (p = 0.158) (Fig. 6c), modularity (p = 0.428) (Fig. 6b) or small-worldness 
(p = 0.087) (Fig. 6d) between cycloserine treated grs357 mutants and wildtype controls. 
After incubation for 3h, clustering was significantly lower in cycloserine treated grs357 
fish compared to the wildtype DMSO control (p = 0.004); characteristic path length (p 
= 0.015) and modularity (p = 0.01) were increased, whereas small-worldness was 
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reduced. These results suggest that cycloserine shows similar effects on network 
parameters as fluoxetine. Network parameters were not significantly different from 
wildtype control fish after application of the drug. However, this effect was not stable: 
after 3h of incubation, the normalizing effect of cycloserine disappears. Cycloserine 
dosage may be decreasing after 1.5h or may reach a concentration at which it acts as 
an NMDA receptor agonist; therefore, its antidepressant potential may be short-lived. 
Kruskal-Wallis test statistics revealed that cycloserine differentially affected 
grs357 mutants and wildtype in several network parameters including clustering and 
small-worldness (Chi square = 47.15, p < 10-5, df = 9). Incubation for 1.5h with 
cycloserine, increased clustering (Fig. 6a; GR DMSO vs. GR cycloserine: p = 0.028) 
and small-worldness (Fig. 6d; GR DMSO vs. GR cycloserine: p = 0.013) in mutants, 
but not in wildtype. This effect of cycloserine in mutants disappeared again after 3 
hours, while clustering (Fig. 6a; WT DMSO vs. WT cycloserine: p = 0.020) and 
small-worldness (Fig. 6d; WT DMSO vs. WT cycloserine: p = 0.002) were reduced, 
and modularity (Fig. 6b; WT DMSO vs. WT cycloserine: p = 0.003) as well as 
characteristic path length (Fig. 6c; WT DMSO vs. WT cycloserine: p = 0.013) were 
increased in wildtype. These results suggest that, for cycloserine, there is a drug x 
genotype interaction over the course of the 3h experiment (Table 1). We assume that, 
after incubation for 1.5h, cycloserine’s antagonistic effect is at its peak and decreasing 
inhibition in the mutant fish brain leads to a highly clustered functional network with 
augmented local and global efficiency in information processing and integration. In 
wildtype brains, we could not observe this effect. After 3h incubation, this effect 
disappeared in the mutant. For wildtype fish, functional connectivity was affected 
after 3h and network parameters are shifted, but interestingly in the opposite direction 
as in mutants. At this point, cycloserine may have increased inhibition in the wildtype 
brain. Due to a potentially higher baseline level of inhibition, this effect was not 
present in the grs357 mutant fish.  
Conclusions and outlook 
Taken together, our results demonstrate that graph analysis of light-sheet 
calcium imaging data is suited to reveal the global correlational structure of zebrafish 
whole-brain activity and has the sensitivity and resolution to detect changes caused by 
genetic or pharmacological perturbations. The construction of graphs from 
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automatically segmented neurons allowed us to extract brain-wide network 
parameters. We propose that exploring drug effects and genotype x drug interactions 
in a computational pipeline that employs rapid light-sheet imaging followed by a first-
pass graph analysis opens up new possibilities for understanding altered brain states 
in zebrafish larvae. Streamlining and further automating this pipeline may enable a 
small-molecule compound screen for the identification of novel antidepressants. In 
the future, this scalable approach can be applied to a variety of zebrafish disease 
models and tailored interventions in order to accelerate our understanding of disease 
conditions and their therapies. 
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Methods 
Animal care and transgenic lines 
All animal procedures conformed to the institutional guidelines of the Max 
Planck Society and the local government (Regierung von Oberbayern). Experimental 
protocols were approved by Regierung von Oberbayern (55.2-1-54-2532-41-2016 and 
55.2-1-54-2532-31-2016). Fish were raised on a 14h light/10h dark cycle at 28°C 
according to standard procedures. Transgenic lines carrying the grs357 mutation were 
generated as described previously (Ziv et al., 2013), and for imaging purposes crossed 
to Tg(elavl3:H2B-GCaMP6s) obtained from Misha Ahrens (Janelia Research 
Campus).  
Light-sheet imaging 
Larvae (grs357/s357 or grs357/+; Tg(elavl3:H2B-GCaMP6s)) were pre-screened for 
expression of the genetically encoded calcium sensor GCaMP6s under the fluorescent 
microscope at 5 dpf. On the following day, fish were embedded in 1.5% low-melting-
point agarose (Invitrogen) in a custom-designed, 3D-printed chamber and aligned to a 
template (see Fig. 1c, d, e). Once hardened, the block of agarose was cut to reduce 
scattering of the beam and immersed in Danieau’s solution to fill a total volume of  
3 ml. Embedded larvae were allowed to accommodate in the setup for at least 30 
minutes before the start of imaging. 
The light-sheet microscope consists of two orthogonal excitation arms for 
frontal and lateral scanning, and a detection arm for imaging from above. A laser 
beam (473 nm wavelength, 3-5 mW power) is split by a dichroic mirror and guided to 
the excitation arms by six dielectric mirrors. Two pairs of mirror galvanometers 
oscillate horizontally and vertically to create a sheet of light (Fig. 1c) and scan the 
sample in z, respectively. Two serial lenses act as a pinhole and focus the sheet into 
the back aperture of a 4x objective. The detection arm consists of a 20x detection 
objective, a piezoelectric component to adjust the focus (10 V displacement, 
corresponds to a 400 µm range in z), a tube lens, fluorescence filter and an Orcaflash 
4.0 sCMOS camera. The chamber containing the sample sits on a lab jack stage, 
which is brought into the field of view of the camera by x, y and z actuators. 
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Spontaneous brain activity of the larvae was imaged with a light sheet 
microscope at 6 ms exposure time and 30 planes in z, resulting a frequency of 2 Hz 
per brain volume for a duration of 5 min in each condition. The ventral-dorsal range 
was specific to every larva, but usually ranged 200 – 224 µm, respectively, resulting 
in a gap of approximately 7 µm between planes. To minimize file size, a binning of 
4x4 pixels was applied, where one pixel width corresponds to 330 nm (before 
binning) and 1.32 µm (after binning), respectively.  
Drug treatment 
In three treatment conditions, the drug compounds (fluoxetine: Sigma-Aldrich, 
CAS No. 56296-78-7; ketamine: Sigma-Aldrich, CAS No. 1867-66-9; cycloserine: 
Sigma-Aldrich, CAS No. 68-41-7) were diluted in DMSO and applied in the setup to 
reach a final concentration of 20µM for each compound. In the control condition, fish 
larvae were incubated with DMSO only. Three light sheet recordings were acquired 
per fish, each lasting 5 min. The first recording was taken right before drug incubation 
started (baseline condition), and the other two were taken after 1.5 and 3 hours of 
incubation with the drug or control medium (see Fig. 1b). For image acquisition, 
genotypes and drug treatments were randomized. We recorded up to three fish per 
day. Overall data from 64 fish were recorded, 8 for each combination of genotype (8 
grs357 mutants, 8 wildtype) and 4 treatments (3 drugs, control). 
Analysis of functional imaging data 
Four-dimensional imaging stacks (time, z, y, x) were split into time series of 
single planes and corrected for motion artifacts using an adapted version of the 
CaImAn package (Pnevmatikakis et al., 2017; Giovannucci et al., 2019). In brief, this 
consists of a rigid transformation, which grossly rotates the images in x and y, 
followed by an optic flow transformation for finer features. Individual neurons were 
detected using a procedure described previously (Portugues et al., 2014). In short, 
regions of interest (ROIs), predominantly corresponding to individual cells, were 
defined as clusters of co-active pixels, using time series correlations of each pixel 
with its neighboring pixels (see Fig. 1f, g). The algorithm picked up between 20,000 
and 40,000 ROIs for each fish brain, of which 10,000 cells were selected randomly to 
construct the functional connectivity matrix used for graph analysis. Activity traces of 
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detected ROIs were only included in the analysis if fluorescence signals varied over 
the time course of the recording. Thereby, stable auto-fluorescence signals of blood, 
eye, skin or pigment cells could be eliminated. Functional connectivity was computed 
as Pearson’s correlation coefficients between signal time series of these ROIs (see 
Fig. 1h). Using MATLAB (R2016b, The MathWorks, Natick, MA) and the Brain 
Connectivity Toolbox (Rubinov & Sporns, 2010), we then calculated the following 
graph-theoretic metrics: the clustering coefficient (reflecting functional segregation in 
the network), the characteristic path length (reflecting functional integration), 
modularity (reflecting the degree of segregation of the network into highly clustered 
modules), and small-worldness (reflecting an optimal balance of functional 
integration and segregation).  
Statistical analysis of network parameters 
The Shapiro-Wilk test was used to test the null hypothesis that data for all 
variables originate from a normally distributed population. For further analysis non-
parametric tests were used, because the test revealed that our data are not normally 
distributed. Network parameters including the clustering coefficient, modularity, 
characteristic path length and small-worldness were analyzed for differences between 
groups of genotypes and drug treatments at baseline and after 1.5h and 3h incubation 
with the Kruskal-Wallis test using the Python module SciPy. Post-hoc testing with the 
Mann-Whitney U test was applied to further explore group differences. To correct for 
multiple comparisons, we used Bonferroni correction. The corrected p value was 
obtained by dividing the original α-value by the number of analyses on the dependent 
variable. In our dataset we performed two comparisons for each variable, the first 
between drug treated mutant and DMSO treated wildtype and the second between 
drug treated and DMSO treated fish within each genotype group. The p values quoted 
in the text are already adjusted, where appropriate, according to these corrections.  
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Figure 1. Experimental workflow. (a) Dysregulated HPA axis in grs357 zebrafish 
mutants. The grs357 mutation abolishes glucocorticoid receptor transcriptional activity 
and thus negative feedback on the stress response, which results in a chronically 
elevated stress axis together with endophenotypes of depression. (b) Experimental 
workflow. The first light-sheet recording before drug application informs about 
baseline brain activity of the two genotypes tested (grs357 mutant, wildtype fish). 
Thereafter, fish are incubated in the setup for 1.5h with fluoxetine (20µM), ketamine 
(20µM), or cycloserine (20µM). DMSO serves as vehicle control. Between the second 
and third recording, fish stay in the setup and incubate for another 1.5h. Graph 
analysis is applied to all three recordings: 0, 1.5h and 3h drug treatment. (c) Sample 
preparation in the light-sheet microscope. Laser beam cross (in blue) on head of larva. 
(d) Top view of embedded larva in a custom chamber. Yellow indicates a block of 
agarose cut along dashed lines. (e) Side view of larva in chamber. (f) CaImAn-
supported ROI detection of neurons in seven representative planes of 30 planes 
acquired per brain. (g) Close up of cellular resolution before (left) and after ROI 
detection (middle), and the randomly selected subsample of ROIs in red for further 
analysis (right). (h) Correlation matrix of functional connectivity. Example of a 
neuron-to-neuron correlation matrix for fluorescence traces of 104 randomly selected 
neurons in one representative fish, as used for network construction and graph 
analysis of functional connectivity. Neurons were sorted by hierarchical clustering 
(not shown).  
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Figure 2. Degree distribution p(k) for different numbers of subsampled neurons. 
Subsampling and the reduction in the number of cells (N) analyzed did not affect the 
statistics of the overall network structure. (Analysis provided by Chas Nelson, 
University of Glasgow) 
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Figure 3. Effect of genotype and drug treatment with fluoxetine on network 
parameters. Mean of the (a) clustering coefficient, (b) modularity, (c) characteristic 
path length and (d) small-worldness in grs357 mutant and wildtype (wt) fish before 
drug treatment (baseline) and after 1.5h and 3h incubation with fluoxetine (20µM) or 
DMSO. 8 fish were imaged for each combination of genotype (grs357, wt) and 
treatment (fluoxetine, control). Error bars represent the standard error of the mean.  
 
 
 
 
 
a b
c d
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Figure 4. Representative examples of the modular organization of functional 
brain networks. (a) Example of a wildtype fish with 2 modules. (b) Example of a 
grs357 mutant fish with 4 modules. (c) Example of a grs357 mutant fish with 2 modules 
after 3h incubation with fluoxetine. 
grs357, elavl3:H2B-GCaMP6s z = - 20 μm  - 40 μm  - 60 μm  - 80 μm
 - 100 μm  - 120 μm  - 140 μm  - 160 μm
wt, elavl3:H2B-GCaMP6s
100 μm
z = - 20 μm
Anterior Posterior
 - 40 μm  - 60 μm  - 80 μm
 - 100 μm  - 120 μm  - 140 μm  - 160 μm
100 μm
grs357 mutant (example): 4 modules
Wildtype (example): 2 modules
a
b
Anterior Posterior
c
grs357 mutant (example 3h incubation with fluoxetine): 2 modules
100 μm
Anterior Posterior
grs357, elavl3:H2B-GCaMP6s z = - 20 μm
 - 100 μm
 - 40 μm  - 60 μm  - 80 μm
 - 120 μm  - 140 μm  - 160 μm
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Box 1. Standard metrics for analysis of whole-brain functional connectivity graphs. 
  
Clustering coefficient: 
The clustering coefficient     describes the fraction of a node’s neighbors that are neighbors
of each other. The global level of clustering      in a network is the average of the local 
clustering coefficients of all the nodes    . 
Clustering on a neuronal level is interpreted as a measure of local efficiency of 
information transfer.
 .
                    
Modularity: 
Modularity describes a subdivision of the network into groups of nodes 
in a way that maximizes the number of within-group edges, and minimizes the number 
of between-group edges. This metric quantifies the degree to which the network may 
be subdivided into such groups.
Modules in a neuronal network might correspond to functional circuits that perform
certain tasks.
Characteristic path length: 
The characteristic path length      is the minimum number of edges between two nodes 
in the network. It is a measure of functional integration with shorter paths implying stronger 
potential for integration. In the brain network it is related to the capability for parallel
information propagation. 
Small-worldness: 
Small-worldness is a property of networks that are highly clustered, like regular lattices, 
yet have small characteristic path lengths, like random graphs. Small-world networks 
possess high local, as well as global, efficiency in signal processing. In our dataset, 
we calculated small-worldness     as the fraction of the mean clustering coefficient and 
the mean characteristic path length of the graph. The functional organization of the brain
appears to be designed with such small-world network characteristics, because it allows 
both highly efficient local information processing in specialized modules and global 
integration at a relatively low wiring cost.
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g
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Fluoxetine 
1.5h 
Fluoxetine 
3h 
Ketamine 
1.5h 
Ketamine 
3h 
Cycloserine 
1.5h 
Cycloserine 
3h 
Clustering 
coefficient 
!! !! "" !" !" "" 
Modularity 
 
"" "" !! "! "" – ! 
Characteristic 
path length 
"" "" !! "! "! – ! 
Small-
worldness 
!! !! !" !" !" – " 
 
Table 1. Drug-induced changes in grs357 mutant (left arrow in blue) and wildtype 
(right arrow in red) network parameters. Compounds that differentially affected 
grs357 mutant and wildtype fish after 1.5h or 3h incubation are highlighted. ! 
indicates an increase in the graph metric; " indicates a decrease; and – indicates no 
change compared to the genotype-specific DMSO control. Dark arrows indicate 
statistical significance; light arrows indicate a non-significant trend. Solid green 
filling indicates a double-sided significant drug x genotype interaction; hatched green 
indicates a significant interaction in one direction.         
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Figure 5. Effect of genotype and drug treatment with ketamine on network 
parameters. Mean of the (a) clustering coefficient, (b) modularity, (c) characteristic 
path length and (d) small-worldness in grs357 mutant and wildtype (wt) fish before 
drug treatment (baseline) and after 1.5h and 3h incubation with ketamine (20µM) or 
DMSO. 8 fish were imaged for each combination of genotype (grs357, wt) and 
treatment (ketamine, control). Error bars represent the standard error of the mean. 
a b
c d
 28 
 
Figure 6. Effect of genotype and drug treatment with cycloserine on network 
parameters. Mean of the (a) clustering coefficient, (b) modularity, (c) characteristic 
path length and (d) small-worldness in grs357 mutant and wildtype (wt) fish before 
drug treatment (baseline) and after 1.5h and 3h incubation with cycloserine (20µM) or 
DMSO. 8 fish were imaged for each combination of genotype (grs357, wt) and 
treatment (cycloserine, control). Error bars represent the standard error of the mean. 
a b
c d
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3 Discussion and outlook 
In the three studies presented in my thesis, I implemented important tools in 
order to establish the zebrafish as a valuable model organism for drug discovery and 
testing. In the first (Barber et al, 2016) and second study (Trads et al., 2016), the 
zebrafish larvae served as a tool to test the effect of a photoswitchable compound on 
neuronal excitability and its implication in controlling locomotor activity. The 
developed compound allows optical control of GIRK channels that play a role in 
balancing excitatory and inhibitory inputs in the brain. The photoswitch is active in the 
dark and isomerizes to its inactive state upon UV irradiation (Barber et al., 2016). 
Because UV light is harmful in living organisms, we improved its design to control it 
with visible light instead (Trads et al., 2016). Using the zebrafish, I performed proof of 
principle experiments for both compounds and demonstrated their potential to 
remotely control behavior in vivo.  
 
In the third study (Burgstaller et al., 2019), I explored the potential of zebrafish 
to implement a scalable method to investigate genetic and pharmacological disruptions 
of whole-brain activity. Performing light-sheet imaging, I recorded spontaneous brain-
wide activity (Ahrens et al., 2013) and analyzed its correlational structure with a 
computational platform based on graph theory (Avitan et al., 2017). Results revealed 
genotype differences in whole-brain functional connectivity and suggest that, 
antidepressants differentially affected particular metrics of the activity graphs, with 
some treatments restoring mutant brain activity to wildtype levels. Importantly, these 
observations are consistent with the broad expression pattern of the glucocorticoid 
receptor throughout the brain. With this new scalable approach for studying and 
quantifying the neural consequences of drug x genotype interactions, the zebrafish 
presents itself as a powerful model organism to develop drugs and innovative 
therapies.  
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3.1 Photoswitchable neuroactive compounds in drug discovery 
Photopharmacology is an emerging field that focuses on the development of 
new photoswitchable compounds with two or more isomeric states. Generally, drug 
development faces many challenges, e.g. poor drug selectivity that results in side 
effects or drug resistance. Exploration and establishment of selective drugs in 
pharmacotherapy that can be spatially and temporally controlled in their action is 
therefore a main goal of clinical research today. Using light to switch between an 
active and inactive state of specific receptors allows local manipulation of distinct 
cells in the body. This may circumvent systemic side effects in clinical application. 
Additionally, these compounds might shed light on biological processes, e.g. enzyme 
activity, GPCR or functional brain connectivity in vivo (Broichhagen et al., 2015; 
Velema et al., 2014). 
 
In the first publication, we generated a photoswitchable GIRK channel agonist 
(LOGO), the first synthetic K+channel opener that selectively targets GIRK channels. 
LOGO is active in the dark as its trans-isomer and acts as GIRK channel agonist that 
efficiently reduces neuronal excitability via hyperpolarization. UV light illumination 
converts LOGO to its significantly less active cis-isomer which results in membrane 
potential depolarization of the targeted cell. GIRK channels are ubiquitously expressed 
throughout the body, especially in the brain. They are an integral part of balancing 
neuronal excitability and therefore also play a role in psychiatric research, e.g. the 
study of depression. Because UV irradiation is harmful to living organisms, the second 
publication was oriented towards improving LOGO in the sense that it can be 
controlled with less harmful, visible light. This project gave rise to VLOGO, a 
photoswitchable compound that facilitates further research of GIRK channels in vivo 
because it is active in the dark and rapidly converts to its significantly less active cis-
isomer upon green light illumination. In my thesis, I contributed to the development 
and improvement of these photoswitchable GIRK channel agonists by testing their 
potential in vivo. For both compounds, I was able to show that they successfully allow 
the control of zebrafish motility in a light dependent manner: in the presence of LOGO 
or VLOGO, the motility of the zebrafish larvae was significantly reduced in response 
to activation of GIRK channels with light stimulation. The ability to remotely and non 
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invasively activate channels, proteins or lipids in the brain of transparent zebrafish 
allows the study of new potential targets for the treatment of psychiatric diseases in 
according fish models. Causality of the function of these targets can be inferred from 
the experimental design because proteins or cell receptors can be switched on and off 
with these photochemicals. This could spur the development of new classes of drugs 
with the zebrafish as a powerful model system for drug discovery. 
 The development and design of photoswitchable compounds that can be 
controlled in time and space has just started. This procedure comes with a vast amount 
of molecular structures and a great variety of drug targets to be explored, but also 
faces many challenges. To begin with, a photoswitchable moiety needs to be present in 
the compound or it should be possible to incorporate it into the drug of interest without 
interfering with its biological activity. Additionally, for clinical use, these switches 
need to be highly selective for the biological target but at the same time thermally and 
metabolically stable, soluble in water, free of toxins and isomerized in both directions, 
ideally with harmless light in the range of 600-1200nm. It is also of great interest to 
consider molecules with two photoisomeric states that differ in their biological activity 
or target. To guarantee that these molecular switches do not interfere with, e.g. neural 
processes when in the field of psychiatric research, the development of 
photocontrolled drugs with fast back-isomerization or isomeres with short-lived 
stability is the route to success (Fehrentz et al., 2011; Velema et al, 2014; Kramer et 
al., 2013).  
  The cross-talk between the field of photoswitches and drug development offers 
a multitude of non-invasive methods to control biological function, e.g. cellular 
networks and neuronal processes. When reading this thesis the question arises how 
these compounds can be used in a clinically relevant context in nontransparent 
organisms. For most applications various studies report efficacy in vitro, e.g. diabetes 
(Broichhagen et al., 2014; Broichhagen et al., 2015; Mehta et al., 2017), pain (Stein et 
al., 2012; Stein et al., 2013; Mourot et al., 2012) or cancer (Borowiak et al., 2015), yet 
only very few studies exist on living organisms. Photoswitches have so far most 
progressed in the field of vision restoration with the advantage of transparency of the 
human eye. Surprisingly, light delivery through nontransparent tissues is not the 
greatest challenge in photopharmacology (Gómez-Santacana et al., 2016). Advances in 
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related fields, e.g. photodynamic therapy approaches or imaging techniques in humans 
have spurred the development of such photoswitchable compounds. Additionally, new 
methods in optogenetics with miniaturized wireless and soft optoelectronic systems 
that can be implanted into the target tissue have greatly contributed to the use of 
photoswitches in vivo (Montgomery et al., 2015; Park et al., 2015; McCall et al., 
2017). 
The common challenges faced today in drug development should not hinder 
the attempt to implement photopharmacology in the pharmaceutical industry. For 
some cases in clinical practice, e.g. when local drug activity without severe side 
effects is desired, photoswitchable drugs lead the way to numerous new applications 
and treatment options. For further optimization of the design and spatiotemporal 
control of photoswitches we have just started to use the zebrafish. It serves as a 
valuable tool with a bright future to implement photopharmacology in the light of 
novel therapeutic applications in the clinic.   
 
3.2 Emerging roles of light-sheet microscopy combined with graph-
theoretical analysis in health and disease 
The main project of my dissertation (Burgstaller et al., 2019) was to explore 
functional connectivity of the whole-brain in healthy and diseased fish. For this, I 
performed light-sheet microscopy recordings in combination with application of drugs, 
which are currently used in stress therapy. Furthermore, I applied the graph-theoretical 
analysis of neuronal network parameters in different genotypes and response to these 
treatments. The aim was to demonstrate the potential of the zebrafish as vehicle for 
investigating mechanism of known pharmaceuticals and to lead the way for discovery 
of new drugs. For that purpose, I used a combined approach of in vivo brain imaging 
and graph-theoretical analysis. 
 First, I evaluated the potential of the grs357 mutant fish to address the research 
goals mentioned above. This fish line carries a mutation in the glucocorticoid receptor 
(grs357) and shows a chronically elevated HPA axis together with high levels of 
cortisol (see Fig. 2). The behavioral phenotype of the grs357 mutant has been described 
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by studies previously performed in our laboratory (Griffith et al., 2012; Ziv et al., 
2013). These studies have shown that mutants swim less, but show an increased startle 
response to unknown auditory stimuli compared to wildtype larvae. The fact that their 
behavior can be normalized by treatment with the SSRI fluoxetine and by commonly 
prescribed anxiolytics (Griffith et al., 2012; Ziv et al., 2013) gave rise to the questions 
addressed in my project. The neuroendocrinological parameters and behavioral profile 
of the grs357 mutant have been dissected, but what remains to be elucidated is how this 
mutation affects brain activity. Is there a behavioral correlate in the sense of altered 
brain function in these fish? And how do the neuroactive compounds that display 
promising therapeutic effects in the fish act on a neuronal level? 
 In the first set of in vivo imaging experiments, I recorded the brain activity of 
the grs357 mutant and wildtype fish at baseline condition (i.e. in absence of external 
stimuli or pharmacological treatment). Extracting network properties revealed baseline 
differences in modularity, with grs357 mutant brains being organized in a greater 
number of functional modules than wildtype brains. These modules have dense within-
connections and sparse between-connections and might correspond to neuronal 
circuits with specific functions in the brain. These results are consistent with studies 
performed in human subjects suffering from major depression, where a greater number 
of modules was found in diseased individuals compared to healthy controls (Ye at al., 
2015). 
For pharmacological experiments, fish were incubated in the setup for 3h with 
fluoxetine, ketamine or cycloserine. Additionally, incubation in DMSO for 3h was 
performed as vehicle control, to quantify the impact of the experimental procedure on 
functional brain connectivity in grs357 mutant and wildtype fish. Analysis of the data 
suggests that grs357 mutant clustering and small-worldness of the functional 
connectivity network is reduced while the characteristic path length is increased 
compared to wildtype fish after 3h. I assume that different effects in both genotypes 
arise because mutant fish have a chronically elevated level of stress hormones, while 
wildtype fish might naturally respond during the time course of the experiment by 
activating their stress axis, which in turn affects network properties. Additionally, 
ceiling effects of the cortisol level on functional connectivity in the grs357 mutant fish 
brain might play a role.  
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 The next set of experiments was performed to explore the potential of 
fluoxetine to normalize disrupted network properties in grs357 mutant fish. At baseline 
measurement, modularity was higher in the grs357 fish and all parameters describing 
functional connectivity revealed genotype differences after 3h in the setup. I could 
show that after treatment with fluoxetine for 1.5h and 3h, network parameters of the 
functional organization in grs357 fish were not different from wildtype fish. The results 
suggest that fluoxetine has the potential to normalize disrupted whole-brain functional 
connectivity and processing in the diseased fish brain. Despite the increasing number 
of publications and advances in the study of antidepressants, the exact mechanism of 
action remains to be elucidated. Furthermore, I did not observe differential effects of 
the drug in the two genotypes. It has been shown that serotonin acts downstream of 
signals from the HPA axis activity (Fox & Lowry, 2013; Ziv et al., 2013). Therefore, I 
assume that fluoxetine action on whole-brain functional connectivity may be 
independent of the animals’ baseline level of stress. 
In addition to exploring the SSRI fluoxetine, I focused on the rapid-acting 
antidepressant ketamine that exerts its antidepressant effect by acting as NMDA 
receptor antagonist that has been shown to modulate zebrafish behavior (Michelotti et 
al., 2018). Analysis of the imaging data revealed that brain networks of ketamine 
treated grs357 fish show similar clustering as wildtype fish. At baseline measurements 
with vehicle control this was not the case. This suggests that ketamine increases the 
clustering coefficient and thereby reduces segregation in the grs357 fish network 
structure. In humans ketamine affects glutamatergic and dopaminergic signaling 
accompanied by transient psychotic symptoms. Thus, the interaction among different 
neurotransmitters in response to treatment with ketamine seems to be highly complex 
(Aalto et al., 2005). Because the drug acts as NMDA receptor antagonist, I assume that 
reduced inhibition in the brain might be the underlying cause for the effects observed 
in the mutant fish brain (Trullas et al., 1990). Interestingly, in wildtype fish ketamine 
reduced clustering compared to the vehicle control. There seems to be a drug x 
genotype interaction that needs to be further defined in future experiments. 
Further experiments were performed with cycloserine, a natural antibiotic 
product of Streptomyces orchidaceus and Streptomyces garyphalus that acts as NMDA 
receptor agonist at low and antagonist at high dosages. The drug has previously been 
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used in tuberculosis therapy. Studies reporting its effect on long-term potentiation, a 
neuronal mechanism thought to be relevant for learning (Watanabe et al., 1992), 
triggered the exploration of its potential for the treatment of neurological and 
psychiatric conditions, e.g. major depression. Incubation with the drug for 1.5h 
showed similar effects on network parameters as treatment with fluoxetine. After 
application of the drug for 1.5h, network parameters were not significantly different 
between grs357 mutant and wildtype control fish. 3h Incubation however revealed that 
this effect is not stable over time. Results suggest that after incubation for 1.5h, 
cycloserine concentration in the fish is at its peak and the compound affects functional 
connectivity by acting as a NMDA receptor antagonist. Its antidepressant potential 
however vanishes after 3h. This is in line with paradoxical effects reported about 
cycloserine facilitating consolidation and retrieval of memory only after acute 
application of high dosages. Chronic exposure to the drug however leads to 
desensitization of receptors in the brain and drug effects disappear (Quartermain et al., 
1994). I assume, after exposure to the drug for 3h, the fish brain has desensitized or 
the compound has, at least to some extent, washed out of the fish system and might act 
as NMDA receptor agonist. In both cases cycloserine might lose its antidepressant 
potential. Moreover, I observed a drug x genotype interaction over the course of the 3h 
experiment. Results suggest that incubation for 1.5h with cycloserine leads to a highly 
clustered functional network with augmented local and global efficiency in 
information processing and integration in grs357 mutant fish. I assume that decreased 
inhibition in the brain due to cycloserine blocking NMDA receptors is responsible for 
these observations. This effect was not present in wildtype fish. However, after 3h 
treatment, this effect disappeared in the grs357 mutant fish. Results suggest that 
cycloserine has washed out after 3h and might act as NMDA agonist at such low 
dosages. In contrast, wildtype fish functional connectivity seems to be affected after 
3h incubation and network parameters are shifted, interestingly in the opposite 
direction as in mutants after 1.5h incubation. This might be due to cycloserine’s effect 
as receptor agonist and is only present in the wildtype fish because in the grs357 
mutant, the level of inhibition in the brain is already high at baseline. 
Despite the detailed analysis of genotype differences and drug effects on 
whole-brain functional connectivity presented in this thesis, further investigation is 
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still necessary for a more detailed analysis of changes in network parameters extracted 
from the recordings. There are several open questions that remain to be solved. Two 
limitations of this project however attracted by far the most attention: a) This project 
investigated functional connectivity of brain networks but did not address any issues 
concerning structural or anatomical correlates, and b) the experimental protocol was 
designed to explore resting state whole-brain activity without using a stimulus and 
therefore does not allow a more concise, regression based analysis of stimulus 
dependent differences in brain activity between genotypes or treatments.  
The first issue raises questions about how these differences manifest on a 
structural level. Are they confined to overall brain activity, or do regional differences 
exist? If the latter is the case, can these be defined anatomically, or is only the 
functional activity and/or coupling affected? To test this, I propose to perform the 
following: To allow averaging of groups, the individual light-sheet recordings can be 
registered to a template brain using the Computational Morphometry Toolkit (CMTK), 
CMTK employs non-rigid transformation followed by morphing algorithms, with 3-
4µm accuracy (Randlett et al., 2015). Modules and clustering between functional units 
can then be mapped back to a standard brain, which allows anatomical localization of 
differences in functional connectivity and comparison between groups of genotypes or 
drug treatments. 
The other major question concerns the experimental procedure. Here, I 
acquired resting-state data without a stimulus protocol. Can we observe differences in 
resting state, and even if so, would a stimulus protocol that induces neural responses 
reveal further genotype or treatment differences? It is likely and the data also shows 
that differences in resting state are rather subtle, yet would the addition of a stimulus 
(visual, auditory, mechanosensory) enhance or suppress those characteristics? We 
assume the latter, and have thus, for the meantime, concentrated on probing the neural 
networks involved in resting state. But to test this in the future, we could perform 
experiments with the grs357 mutant and wildtype fish that incorporate visual stimuli to 
identify specific regions in the brain that might show genotype specific activation in 
response to the environment. These regions could then, in a next step, be 
optogenetically stimulated and behavior could simultaneously be recorded to establish 
causal relationships between neuronal activity and its behavioral implementation.  
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The scalability of light-sheet microscopy for drug discovery has already been 
successfully demonstrated. Lin et al. (2018) describe an in vivo drug screening strategy 
that combines high-throughput technology to generate large-scale brain activity maps 
(BAMs) with machine learning for predictive analysis. In their approach, drug effects 
and potential therapeutic uses can be evaluated based on information-rich BAMs 
derived from drug-treated zebrafish larvae. From a screen of clinically used drugs, 
they identified coherent drug clusters that are associated with known therapeutic 
categories (Lin et al., 2018). However, different incubation times or dosages were not 
included and analysis was constrained to a projection of whole-brain cell activity in 
one 2D plane. Our analysis platform provides a valuable complementation of this 
approach because it allows a much more detailed analysis of functional brain-wide 
activity and the study of individual drug action beyond simply clustering compounds 
based on similarity in their effects. 
 
3.3 Outlook 
I conclude that with my work I could demonstrate the graph-theoretical 
analysis approach applied to whole-brain data as a successful method to determine 
changes in functional network connectivity after drug treatment. The identification of 
a zebrafish model with a mutation in the glucocorticoid receptor has provided an 
opportunity to study the pathogenesis of depression. Construction of graphs from cells 
and their functional connections allows the analysis of complex changes in whole-
brain network parameters. I propose that exploring genotype x drug interactions in 
imaging assays with graph-theoretical characterization of functional whole-brain 
connectivity opens up new possibilities for understanding the depressed brain state and 
for identifying novel therapeutic avenues for the treatment of stress-related disorders. 
In the future, this scalable approach with the zebrafish as promising vehicle for drug 
discovery can be applied to a variety of disease genotypes and compounds to 
accelerate our understanding of drug action in neurobiology.  
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